10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the quarterly period ended September 30, 2019

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 1-37774

 AdvanSix Inc.

(Exact name of registrant as specified in its charter)

Delaware	81-2525089
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

300 Kimball Drive, Suite 101, Parsippany, New Jersey	07054
(Address of principal executive offices)	(Zip Code)

(973) 526-1800

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.01 per share	ASIX	New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý  No o 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý  No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ý	Accelerated filer  o	Non-accelerated filer  o	Smaller reporting company ☐
			Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No ý

The Registrant had 27,912,355 shares of common stock, $0.01 par value, outstanding at October 25, 2019.

ADVANSIX INC.

FORM 10-Q

TABLE OF CONTENTS

Part I.	FINANCIAL INFORMATION
Item 1.	Financial Statements	3
	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2019 and 2018 (unaudited)	3
	Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2019 and 2018 (unaudited)	4
	Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2019 and 2018 (unaudited)	6
	Condensed Consolidated Statements of Stockholders' Equity for the Nine Months Ended September 30, 2019 and 2018 (unaudited)	7
	Notes to Condensed Consolidated Financial Statements (unaudited)	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	28
Item 4.	Controls and Procedures	29
Part II.	OTHER INFORMATION	29
Item 1.	Legal Proceedings	29
Item 1A.	Risk Factors	29
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 6.	Exhibits	31
	Signature	32

ITEM 1. FINANCIAL STATEMENTS

ADVANSIX INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(Dollars in thousands, except share and per share amounts)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Sales	$	310,633	$	368,653	$	970,743	$	1,128,350
Costs, expenses and other:
Costs of goods sold	280,123		343,434		850,131		1,007,712
Selling, general and administrative expenses	19,261		18,057		58,683		55,189
Other non-operating expense (income), net	1,815		1,453		4,871		6,581
Total costs, expenses and other	301,199		362,944		913,685		1,069,482
Income before taxes	9,434		5,709		57,058		58,868
Income tax expense	1,513		229		13,617		13,385
Net income	$	7,921	$	5,480	$	43,441	$	45,483
Earnings per common share
Basic	$	0.29	$	0.18	$	1.54	$	1.50
Diluted	$	0.28	$	0.18	$	1.49	$	1.46
Weighted average common shares outstanding
Basic	27,608,985		30,160,991		28,192,760		30,375,873
Diluted	28,581,451		30,983,834		29,164,024		31,189,640

See accompanying notes to Condensed Consolidated Financial Statements.

3

ADVANSIX INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(Dollars in thousands)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Net income	$	7,921	$	5,480	$	43,441	$	45,483
Foreign exchange translation adjustment	(20)		(8)		(17)		(26)
Cash-flow hedges	(439)		—		(1,060)		—
Pension obligation adjustments	—		—		—		410
Other comprehensive income (loss), net of tax	(459)		(8)		(1,077)		384
Comprehensive income	$	7,462	$	5,472	$	42,364	$	45,867

See accompanying notes to Condensed Consolidated Financial Statements.

4

ADVANSIX INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(Dollars in thousands, except share and per share amounts)

	September 30, 2019		December 31, 2018
ASSETS
Current assets:
Cash and cash equivalents	$	10,048	$	9,808
Accounts and other receivables – net	109,292		160,266
Inventories – net	162,479		137,182
Other current assets	8,433		3,807
Total current assets	290,252		311,063
Property, plant and equipment – net	731,643		672,210
Operating lease right-of-use assets	136,122		—
Goodwill	15,005		15,005
Other assets	38,795		36,348
Total assets	$	1,211,817	$	1,034,626
LIABILITIES
Current liabilities:
Accounts payable	$	219,225	$	231,720
Accrued liabilities	29,839		30,448
Operating lease liabilities – short-term	35,656		—
Deferred income and customer advances	1,948		22,556
Total current liabilities	286,668		284,724
Deferred income taxes	112,579		103,783
Operating lease liabilities – long-term	100,752		—
Line of credit – long-term	266,000		200,000
Postretirement benefit obligations	22,581		21,080
Other liabilities	6,011		4,701
Total liabilities	794,591		614,288
COMMITMENTS AND CONTINGENCIES (Note 9)
STOCKHOLDERS' EQUITY
Common stock, par value $0.01; 200,000,000 shares authorized; 30,600,708 shares issued and 27,481,162 outstanding at September 30, 2019; 30,555,715 shares issued and 29,345,001 outstanding at December 31, 2018	306		306
Preferred stock, par value $0.01; 50,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2019 and December 31, 2018	—		—
Treasury stock at par (3,119,546 shares at September 30, 2019; 1,210,714 shares at December 31, 2018)	(31)		(12)
Additional paid-in capital	189,242		234,699
Retained earnings	231,260		187,819
Accumulated other comprehensive loss	(3,551)		(2,474)
Total stockholders' equity	417,226		420,338
Total liabilities and stockholders' equity	$	1,211,817	$	1,034,626

See accompanying notes to Condensed Consolidated Financial Statements.

5

ADVANSIX INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(Dollars in thousands)

	Nine Months Ended September 30,
	2019		2018
Cash flows from operating activities:
Net income	$	43,441	$	45,483
Adjustments to reconcile net income to net cash (used for) provided by operating activities:
Depreciation and amortization	42,094		38,905
Loss on disposal of assets	4,967		1,560
Deferred income taxes	9,149		8,816
Stock based compensation	7,575		7,506
Accretion of deferred financing fees	320		1,696
Restructuring charges	12,623		—
Changes in assets and liabilities:
Accounts and other receivables	51,136		46,878
Inventories	(26,739)		14,182
Accounts payable	(12,844)		(10,675)
Accrued liabilities	(4,470)		(9,703)
Deferred income and customer advances	(20,608)		(14,899)
Other assets and liabilities	(6,108)		(2,014)
Net cash provided by operating activities	100,536		127,735
Cash flows from investing activities:
Expenditures for property, plant and equipment	(106,386)		(72,650)
Other investing activities	(2,203)		(1,656)
Net cash used for investing activities	(108,589)		(74,306)
Cash flows from financing activities:
Payments of long-term debt	—		(266,625)
Borrowings from line of credit	316,750		284,500
Payments of line of credit	(250,750)		(84,500)
Payment of line of credit facility fees	—		(1,362)
Principal payments of finance leases	(4,656)		(225)
Purchase of treasury stock	(53,067)		(20,443)
Issuance of common stock	16		—
Net cash provided by (used for) financing activities	8,293		(88,655)
Net change in cash and cash equivalents	240		(35,226)
Cash and cash equivalents at beginning of period	9,808		55,432
Cash and cash equivalents at the end of period	$	10,048	$	20,206
Supplemental non-cash investing activities:
Capital expenditures included in accounts payable	$	27,344	$	17,649
Supplemental cash activities:
Cash paid for interest	$	3,519	$	4,406
Cash paid for income taxes	$	6,949	$	7,254

See accompanying notes to Condensed Consolidated Financial Statements.

6

ADVANSIX INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)

(Dollars in thousands)

	Common Stock			Additional Paid-In Capital		Retained Earnings (Accumulated Deficit)		Treasury Stock		Accumulated  Other Comprehensive Income (Loss)		Total Equity
	Shares	Amount
Balance at December 31, 2018	30,555,715	$	306	$	234,699	$	187,819	$	(12)	$	(2,474)	$	420,338
Net Income	—	—		—		20,174		—		—		20,174
Comprehensive income
Foreign exchange translation adjustments	—	—		—		—		—		(1)		(1)
Cash-flow Hedges	—	—		—		—		—		(192)		(192)
Pension obligation adjustments	—	—		—		—		—		—		—
Other comprehensive income (loss), net of tax	—	—		—		—		—		(193)		(193)
Issuance of common stock	22,497	—		16		—		—		—		16
Purchase of treasury stock (793,754 shares)	—	—		(23,845)		—		(8)		—		(23,853)
Stock-based compensation	—	—		2,762		—		—		—		2,762
Balance at March 31, 2019	30,578,212	306		213,632		207,993		(20)		(2,667)		419,244
Net Income	—	—		—		15,346		—		—		15,346
Comprehensive income
Foreign exchange translation adjustments	—	—		—		—		—		4		4
Cash-flow Hedges	—	—		—		—		—		(429)		(429)
Pension obligation adjustments	—	—		—		—		—		—		—
Other comprehensive income (loss), net of tax	—	—		—		—		—		(425)		(425)
Issuance of common stock	13,260	—		—		—		—		—		—
Purchase of treasury stock (578,045 shares)	—	—		(16,408)		—		(6)		—		(16,414)
Stock-based compensation	—	—		2,812		—		—		—		2,812
Balance at June 30, 2019	30,591,472	306		200,036		223,339		(26)		(3,092)		420,563
Net Income	—	—		—		7,921		—		—		7,921
Comprehensive income
Foreign exchange translation adjustments	—	—		—		—		—		(20)		(20)
Cash-flow Hedges	—	—		—		—		—		(439)		(439)
Pension obligation adjustments	—	—		—		—		—		—		—
Other comprehensive income (loss), net of tax	—	—		—		—		—		(459)		(459)
Issuance of common stock	9,236	—		—		—		—		—		—
Purchase of treasury stock (537,033 shares)	—	—		(12,795)		—		(5)		—		(12,800)
Stock-based compensation	—	—		2,001		—		—		—		2,001
Balance at September 30, 2019	30,600,708	$	306	$	189,242	$	231,260	$	(31)	$	(3,551)	$	417,226

7

ADVANSIX INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)

(Dollars in thousands)

	Common Stock			Additional Paid-In Capital		Retained Earnings (Accumulated Deficit)		Treasury Stock		Accumulated  Other Comprehensive Income (Loss)		Total Equity
	Shares	Amount
Balance at December 31, 2017	30,482,966	$	305	$	263,081	$	121,985	$	—	$	(9,046)	$	376,325
Net Income	—	—		—		11,593		—		—		11,593
Comprehensive income
Foreign exchange translation adjustments	—	—		—		—		—		(1)		(1)
Cash-flow Hedges	—	—		—		—		—		—		—
Pension obligation adjustments	—	—		—		(410)		—		410		—
Other comprehensive income (loss), net of tax	—	—		—		(410)		—		409		(1)
Issuance of common stock	25,356											—
Purchase of treasury stock (8,995 shares)	—	—		(370)		—		—		—		(370)
Stock-based compensation	—	—		2,281		—		—		—		2,281
Balance at March 31, 2018	30,508,322	305		264,992		133,168		—		(8,637)		389,828
Net Income	—	—		—		28,410		—		—		28,410
Comprehensive income
Foreign exchange translation adjustments	—	—		—		—		—		(17)		(17)
Cash-flow Hedges	—	—		—		—		—		—		—
Pension obligation adjustments	—	—		—		—		—		—		—
Other comprehensive income (loss), net of tax	—	—		—		—		—		(17)		(17)
Issuance of common stock	16,416	—		—		—		—		—		—
Purchase of treasury stock (70,107 shares)	—	—		(2,742)		—		(1)		—		(2,743)
Stock-based compensation	—	—		2,599		—		—		—		2,599
Balance at June 30, 2018	30,524,738	305		264,849		161,578		(1)		(8,654)		418,077
Net Income	—	—		—		5,480		—		—		5,480
Comprehensive income
Foreign exchange translation adjustments	—	—		—		—		—		(8)		(8)
Cash-flow Hedges	—	—		—		—		—		—		—
Pension obligation adjustments	—	—		—		—		—		—		—
Other comprehensive income (loss), net of tax	—	—		—		—		—		(8)		(8)
Issuance of common stock	30,977	1		—		—		—		—		1
Purchase of treasury stock (485,145 shares)	—	—		(17,326)		—		(5)		—		(17,331)
Stock-based compensation	—	—		2,626		—		—		—		2,626
Balance at September 30, 2018	30,555,715	$	306	$	250,149	$	167,058	$	(6)	$	(8,662)	$	408,845

See accompanying notes to Condensed Consolidated Financial Statements.

8

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

1. Organization, Operations and Basis of Presentation

Description of Business

AdvanSix Inc. (“AdvanSix”, the “Company”, "we" or "our") is an integrated manufacturer of Nylon 6, a polymer resin which is a synthetic material used by our customers to produce engineered plastics, fibers, filaments and films that, in turn, are used in such end-products as automotive and electronic components, carpets, sports apparel, fishing nets and food and industrial packaging. As a result of our backward integration and the configuration of our manufacturing facilities, we also sell a variety of other products, all of which are produced as part of our integrated Nylon 6 resin manufacturing process including caprolactam, ammonium sulfate fertilizers, acetone and other chemical intermediates.

Basis of Presentation

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Rule 10-01 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of September 30, 2019, and its results of operations for the three and nine months ended September 30, 2019 and 2018 and cash flows for the nine months ended September 30, 2019 and 2018. The Condensed Consolidated Balance Sheet at December 31, 2018 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year.  These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (the "2018 Form 10-K"). All intercompany transactions have been eliminated.

Certain prior period amounts have been reclassified for consistency with the current period presentation.

It is our practice to establish actual quarterly closing dates using a predetermined fiscal calendar, which requires our businesses to close their books on a Saturday in order to minimize the potentially disruptive effects of quarterly closing on our business processes. Historically, the effects of this practice were generally not significant to reported results for any quarter and only existed within a reporting year. In the event that differences in actual closing dates are material to year-over-year comparisons of quarterly or year-to-date results, we will provide the appropriate disclosures. Our actual closing dates for the three and nine months ended September 30, 2019 and 2018 were September 28, 2019 and September 29, 2018, respectively.

Liabilities to creditors to whom we have issued checks that remained outstanding at September 30, 2019 and December 31, 2018 aggregated $5.4 million and $7.7 million, respectively, and were included in Cash and cash equivalents and Accounts payable in the Condensed Consolidated Balance Sheets.

The Company submitted a business interruption insurance claim related to the first quarter 2018 weather event and recorded a benefit of $6.6 million and $2.3 million to Cost of goods sold in the first and second quarters of 2019, respectively. The business interruption claim was closed during the second quarter of 2019 with a total recorded benefit of approximately of $12 million.

On May 4, 2018, the Company announced that its Board of Directors (the “Board”) authorized a share repurchase program of up to $75 million of the Company’s common stock. On February 22, 2019, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity available under the May 2018 share repurchase program. Repurchases may be made from time to time on the open market, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.

9

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

As of September 30, 2019, the Company had repurchased 3,089,762 shares of common stock for an aggregate of $90.4 million at a weighted average market price of $29.26 per share. As of September 30, 2019, $59.6 million remained available for share repurchases under the current authorization.

2. Recent Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations.

In October 2018, the FASB issued ASU No. 2018-16, Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (“SOFR”) Overnight Index Swap (“OIS”) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes, which permits use of the OIS rate based on SOFR as a U.S. benchmark interest rate for hedge accounting purposes under Topic 815 in addition to the interest rates on direct Treasury obligations of the U.S. government (“UST”), the LIBOR swap rate, the OIS rate based on the Fed Funds Effective Rate and the SIFMA Municipal Swap Rate. Pursuant to the amendments, SOFR will be an option to replace LIBOR as it is phased out. The amendments of ASU No. 2018-16 are effective for companies that have adopted ASU 2017-12 for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year or at such time a company adopts ASU 2017-12. Early adoption of ASU 2018-16 is not permitted without previous adoption of ASU 2017-12. As the Company elected to early adopt ASU 2017-12 during the fourth quarter of 2018, the Company adopted ASU 2018-16 effective January 1, 2019, which did not have a material impact on the Company's consolidated financial position or results of operations upon adoption.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize most leases on their balance sheets related to the rights and obligations created by those leases. The new standard also requires disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will be effective for interim and annual periods beginning after December 15, 2018 (early adoption is permitted). Initial guidance stated that the new standard be applied under a modified retrospective approach with periods prior to the adoption date being adjusted. During July 2018, however, the FASB issued ASU 2018-11, Leases (Topic 842), providing another transition method allowing a company to recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption without adjusting prior periods. The Company adopted the standard effective January 1, 2019 electing the cumulative-effect adjustment approach made available in ASU 2018-11. The Company has also elected the following practical expedients:

•the package of three expedients which allows the Company not to re-assess (i) whether any expired or existing contracts are or contain leases, (ii) lease classification for any expired or existing leases, and (iii) initial direct costs for any expired or existing leases;

•the short-term lease practical expedient, which allows the Company to exclude leases with an initial term of 12 months or less (“short-term leases”) from recognition in the unaudited Condensed Consolidated Balance Sheet;

•the bifurcation of lease and non-lease components practical expedients, which did not require the Company to bifurcate lease and non-lease components for our real estate leases; and

•the land easements practical expedient, which allows the Company to carry forward the accounting treatment for land easements on existing agreements.

We have implemented internal controls and key system functionality to enable the preparation of financial information on adoption. The standard had a material impact to our Condensed Consolidated Balance Sheet but did not have a significant impact in the recognition, measurement or presentation of lease expenses within the Condensed Consolidated Statements of Operations or the Condensed Consolidated Statements of Cash Flows. The most significant impact was the recognition of right-of-use (“ROU”) assets and liabilities for operating leases, while our accounting for finance leases remained substantially unchanged. See "Note 8. Leases" for further information.

3. Revenues

Revenue Recognition

We serve approximately 400 customers annually in more than 40 countries and across a wide variety of industries. For the three months ended September 30, 2019 and 2018, the Company's ten largest customers accounted for approximately 51% and 48% of total sales, respectively. For the nine months ended September 30, 2019 and 2018, the Company's ten largest customers accounted for approximately 47% and 45% of total sales, respectively.

10

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

We typically sell to customers under master service agreements, with one- to two-year terms on average, or by purchase orders. We have historically experienced low customer turnover and have an average customer relationship of approximately 20 years. Our largest customer is Shaw Industries Group Inc. (“Shaw”), one of the world's largest consumers of caprolactam and Nylon 6 resin. We sell Nylon 6 resin and caprolactam to Shaw under a long-term agreement. For the three months ended September 30, 2019 and 2018, our sales to Shaw were 23% and 22%, respectively, of our total sales. For the nine months ended September 30, 2019 and 2018, our sales to Shaw were 21% and 22%, respectively, of our total sales.

Each of the Company’s product lines represented the following approximate percentage of total sales for the three and nine months ended September 30, 2019 and 2018:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019	2018
Nylon	25%	28%	28%	28%
Caprolactam	26%	18%	22%	18%
Ammonium Sulfate Fertilizers	20%	19%	23%	20%
Chemical Intermediates	29%	35%	27%	34%
	100%	100%	100%	100%

The Company's revenues by geographic area for the three and nine months ended September 30, 2019 and 2018 were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	250,056	$	306,050	$	797,249	$	946,195
International	60,577		62,603		173,494		182,155
Total	$	310,633	$	368,653	$	970,743	$	1,128,350

Deferred Income and Customer Advances

The Company defers revenues when cash payments are received in advance of our performance. Customer advances relate primarily to sales from the ammonium sulfate business. Below is a roll-forward of Deferred income and customer advances for the nine months ended September 30, 2019:

Opening balance January 1, 2019	$	22,556
Additions to deferred revenues	1,083
Less amounts recognized in revenues	(21,691)
Ending balance September 30, 2019	$	1,948

The Company expects to recognize as revenue the September 30, 2019 ending balance of Deferred income and customer advances within one year or less.

4. Earnings Per Share

The computation of basic and diluted earnings per share ("EPS") is based on Net income divided by the basic weighted average number of common shares and diluted weighted average number of common shares, respectively. The details of the basic and diluted EPS calculations for the three and nine months ended September 30, 2019 and 2018 were as follows:

11

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Basic
Net Income	$	7,921	$	5,480	$	43,441	$	45,483
Weighted average common shares outstanding	27,608,985		30,160,991		28,192,760		30,375,873
EPS – Basic	$	0.29	$	0.18	$	1.54	$	1.50
Diluted
Dilutive effect of equity awards and other stock-based holdings	972,466		822,843		971,264		813,767
Weighted average common shares outstanding	28,581,451		30,983,834		29,164,024		31,189,640
EPS – Diluted	$	0.28	$	0.18	$	1.49	$	1.46

Diluted EPS is computed based upon the weighted average number of common shares outstanding for the period plus the dilutive effect of common stock equivalents (which includes units allocated to the AdvanSix stock unit fund under the AdvanSix Inc. Deferred Compensation Plan) using the treasury stock method and the average market price of our common stock for the year.

The diluted EPS calculations exclude the effect of stock options when the options’ assumed proceeds exceed the average market price of the common shares during the period. The anti-dilutive common stock equivalents outstanding at the three and nine months ended September 30, 2019 and 2018 were as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019	2018
Options and stock equivalents	658,327	135,535	509,401	130,535

5. Accounts and Other Receivables – Net

	September 30, 2019		December 31, 2018
Accounts receivables	$	108,832	$	166,017
Other	2,320		1,716
Total accounts and other receivables	111,152		167,733
Less – allowance for doubtful accounts	(1,860)		(7,467)
Total accounts and other receivables – net	$	109,292	$	160,266

The decrease in Total accounts and other receivables – net at September 30, 2019 versus December 31, 2018 was due primarily to lower sales and increased collections related to a trade receivables discount arrangement with a third-party financial institution. The change in the allowance for doubtful accounts relates primarily to an accounts receivable write-off of approximately $5.1 million related to a customer bankruptcy as previously reported in the 2018 Form 10-K.

6. Inventories

12

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

	September 30, 2019		December 31, 2018
Raw materials	$	46,714	$	55,002
Work in progress	65,146		46,728
Finished goods	57,558		39,368
Spares and other	24,618		24,555
	194,036		165,653
Reduction to LIFO cost basis	(31,557)		(28,471)
Total inventories – net	$	162,479	$	137,182

The increase in Total inventories – net at September 30, 2019 compared to the balance at December 31, 2018 was due primarily to increased Work in progress and Finished goods inventory due to sales timing, product mix and buffer inventory build ahead of the Company's planned fourth quarter 2019 turnaround partially offset by lower levels of Raw materials driven by the timing of cumene deliveries.

7. Postretirement Benefit Cost

The components of Net periodic benefit cost of the Company’s pension plan are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Service cost	$	1,714	$	2,001	$	5,141	$	6,004
Interest cost	521		469		1,563		1,407
Expected return on plan assets	(334)		(287)		(1,002)		(862)
Net periodic benefit cost	$	1,901	$	2,183	$	5,702	$	6,549

The Company made contributions to the defined benefit pension plan of $4.2 million during the nine months ended September 30, 2019 sufficient to satisfy pension funding requirements for 2019 under the AdvanSix Retirement Earnings Plan. The Company made contributions of $0 in the first quarter of 2019, $0.5 million in the second quarter of 2019 and $3.7 million in the third quarter of 2019. The Company does not plan to make additional pension plan contributions during the fourth quarter of 2019, but plans to make additional contributions in future years sufficient to satisfy pension funding requirements in those periods.

The pension plan assets are invested through a master trust fund. The strategic asset allocation for the trust fund is selected by the Company's Investment Committee reflecting the results of comprehensive asset and liability modeling. The Investment Committee establishes strategic asset allocation percentage targets and appropriate benchmarks for significant asset classes with the aim of achieving a prudent balance between return and risk.

8. Leases

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use assets, Operating lease liabilities – short-term, and Operating lease liabilities – long-term in our Condensed Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment – net, Accounts payable, and Other liabilities in our Condensed Consolidated Balance Sheets.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease pre-payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease and, when it is reasonably certain that such an option will be exercised, it is included in the determination of the corresponding assets and

13

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

liabilities. Short-term leases are not recognized on our unaudited Condensed Consolidated Balance Sheets. Lease expense for all lease payments is recognized on a straight-line basis over the lease term.

We have lease agreements with lease and non-lease components, which are generally accounted for separately. Additionally, for certain equipment leases, we apply a portfolio approach to effectively account for the operating lease ROU assets and liabilities. The Company has entered into agreements to lease transportation equipment, storage facilities, office space, dock access and other equipment. The leases have initial terms of up to 20 years with some containing renewal options subject to customary conditions.

The components of lease expense were as follows:

	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Finance lease cost:
Amortization of right-of-use asset	$	172	$	477
Interest on lease liabilities	18		52
Total finance lease cost	190		529
Operating lease cost	9,874		25,375
Short-term lease cost	2,527		10,924
Total lease cost	$	12,591	$	36,828

Supplemental cash flow information related to leases was as follows:

	Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	25,089
Operating cash flows from finance leases	48
Financing cash flows from finance leases	4,656
Non-cash information:
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	38,324
Finance leases	872

Supplemental balance sheet information related to leases was as follows:

14

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

	September 30, 2019
Operating Leases
Operating lease right-of-use assets	$	136,122
Operating lease liabilities – short term	35,656
Operating lease liabilities – long term	100,752
Total operating lease liabilities	$	136,408
Finance Leases
Property, plant and equipment – gross	$	2,633
Accumulated depreciation	(1,206)
Property, plant and equipment – net	$	1,427
Accounts payable	676
Other liabilities	768
Total finance lease liabilities	$	1,444
Weighted Average Remaining Lease Term
Operating leases	9.2 years
Finance leases	2.3 years
Weighted Average Discount Rate
Operating leases	5.75		%
Finance leases	4.87		%

The cumulative effect of the changes made to the Condensed Consolidated Balance Sheets for the adoption of the new leasing standard on January 1, 2019 was as follows:

	Balance Sheet accounts prior to new leasing standard adoption adjustments		Adjustments due to the adoption of the new leasing standard		Balance Sheet accounts after the new leasing standard adoption adjustments
ASSETS
Property, plant and equipment – net	$	1,032	$	—	$	1,032
Operating lease right-of-use assets	—		117,921		117,921
Total assets	1,034,626		$	117,921	1,152,547
LIABILITIES AND EQUITY
Current Liabilities:
Accounts payable	$	318	$	—	$	318
Operating lease liabilities – short term	—		24,794		24,794
Total current liabilities	284,724		24,794		309,518
Operating lease liabilities – long term	—		93,127		93,127
Other liabilities	762		—		762
Total liabilities	614,288		117,921		732,209
Total equity	420,338		—		420,338
Total liabilities and equity	1,034,626		$	117,921	1,152,547

Maturities of lease liabilities were as follows:

15

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

Year Ending December 31,	Operating Leases		Finance Leases
2019 (remainder)	$	10,987	$	194
2020	41,576		708
2021	29,838		472
2022	20,578		151
2023	12,391		—
Thereafter	70,375		—
Total lease payments	185,745		1,525
Less imputed interest	(49,337)		(81)
Total	$	136,408	$	1,444

As previously disclosed in our 2018 Form 10-K and under the previous lease accounting standard, future minimum lease payments for leases having initial or remaining non-cancellable lease terms in excess of one year were as follows:

Year Ending December 31,	Operating Leases		Capital Leases
2019	$	36,110	$	239
2020	29,318		212
2021	16,111		131
2022	11,571		89
2023	9,104		—
Thereafter	26,627		—
Total lease payments	$	128,841	$	671

9. Commitments and Contingencies

The Company is subject to a number of lawsuits, investigations and disputes, some of which involve substantial amounts claimed, arising out of the conduct of the Company or other third-parties in the normal and ordinary course of business. A liability is recognized for any contingency that is probable of occurrence and reasonably estimable. The Company continually assesses the likelihood of adverse judgments or outcomes in these matters, as well as potential ranges of possible losses (taking into consideration any insurance recoveries), based on an analysis of each matter with the assistance of legal counsel and, if applicable, other experts.

Given the uncertainty inherent in such lawsuits, investigations and disputes, the Company does not believe it is possible to develop estimates of reasonably possible loss in excess of current accruals for these matters. Considering the Company’s past experience and existing accruals, the Company does not expect the outcome of these matters, either individually or in the aggregate, to have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. Potential liabilities are subject to change due to new developments, changes in settlement strategy or the impact of evidentiary requirements, which could cause the Company to pay damage awards or settlements (or become subject to equitable remedies) that could have a material adverse effect on the Company’s consolidated results of operations, balance sheet and/or operating cash flows in the periods recognized or paid.

We assumed from Honeywell all health, safety and environmental (“HSE”) liabilities and compliance obligations related to the past and future operations of our current business, as well as all HSE liabilities associated with our three current manufacturing locations and the other locations used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to be material for 2019.

10. Income Taxes

16

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

The Company’s provision for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The provision for income taxes was $1.5 million and $0.2 million for the three months ended September 30, 2019 and 2018, respectively. The provision for income taxes was $13.6 million and $13.4 million for the nine months ended September 30, 2019 and 2018, respectively.

In the current period, the Company recorded an income tax benefit of $0.9 million in connection with the filing of the 2018 U.S. federal income tax return primarily attributable to additional research tax credits claimed in 2018. This resulted in a 9.9% and 1.6% decrease to the Company’s effective tax rate for the three and nine months ended September 30, 2019, respectively. In the period ended September 30, 2018, the Company recorded a net $1.0 million income tax benefit in connection with the filing of the 2017 U.S. federal income tax return and the accounting under ASC 740 (Staff Accounting Bulletin No. 118) for the Tax Cuts and Jobs Act ("Tax Act") . These adjustments resulted in a 18.2% and 1.8% decrease to the Company’s effective tax rate for the three and nine months ended September 30, 2018, respectively.

11. Fair Value Measurements

Financial and non-financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. During the fourth quarter of 2018, the Company acquired a royalty stream which has been treated as an asset acquisition. The purchase price of the royalty stream for $1.0 million approximated its fair value at December 31, 2018 and is considered a Level 3 asset. The fair value measurement is based on the expected future cash flows and, as there is no reason to believe that the asset is impaired, it is assumed that the valuation remains unchanged at September 30, 2019. In November 2018 and July 2019, the Company entered into two interest rate swap transactions related to its credit agreement. The fair value of the interest rate swaps at September 30, 2019 was a loss of approximately $2.2 million and is considered a Level 2 liability.

The pension plan assets are invested in collective investment trust funds. These investments are measured at fair value using the net asset value per share as a practical expedient. Investments valued using the net asset value method (NAV) (or its equivalent) practical expedient are excluded from the fair value hierarchy disclosure.

The Company’s Condensed Consolidated Balance Sheets also include Cash and cash equivalents, Accounts receivable and Accounts payable all of which are recorded at amounts which approximate fair value.

The Company also has assets that are required to be recorded at fair value on a non-recurring basis. These assets are evaluated when certain triggering events occur (including a decrease in estimated future cash flows) that indicate the asset should be evaluated for impairment. Goodwill and indefinite lived intangible assets must be evaluated at least annually.

12. Derivative and Hedging Instruments

The specific credit and market, commodity price and interest rate risks to which the Company is exposed in connection with its ongoing business operations are described below. This discussion includes an explanation of the hedging instrument, interest rate swap agreements, used to manage the Company’s interest rate risk associated with a fixed and floating-rate borrowing.

For cash flow hedges, the entire change in the fair value of the hedging instrument included in the assessment of hedge effectiveness is recorded in Other comprehensive income. Those amounts are reclassified to earnings in the same income statement line item that is used to present the earnings effect of the hedged item when the hedged item affects earnings.

Credit and Market Risk – Financial instruments, including derivatives, expose the Company to counterparty credit risk for non-performance and to market risk related to changes in commodity prices, interest rates and foreign currency exchange rates. The Company manages its exposure to counterparty credit risk through specific minimum credit standards, diversification of counterparties, and procedures to monitor concentrations of credit risk. The Company’s counterparties in derivative transactions are substantial investment and commercial banks with significant experience using such derivative instruments. The Company monitors the impact of market risk on the fair value and cash flows of its derivative and other financial instruments considering reasonably possible changes in commodity prices, interest rates and foreign currency exchange rates and restricts the use of derivative financial instruments to hedging activities.

The Company continually monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. The terms and conditions of credit sales are designed to mitigate or eliminate concentrations of credit risk with any

17

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

single customer. Although the Company did not have any customers accounting for a significant percentage of trade Accounts receivable - net at September 30, 2019, one customer accounted for approximately 22% of trade Accounts receivable – net at December 31, 2018.

Commodity Price Risk Management – The Company's exposure to market risk for commodity prices can result in changes in the cost of production. We primarily mitigate our exposure to commodity price risk by using long-term, formula-based price contracts with our suppliers and formula-based price agreements with customers. Our customer agreements provide for price adjustments based on relevant market indices and raw material prices and generally do not include take-or-pay terms. We may also enter into forward commodity contracts with third-parties designated as hedges of anticipated purchases of several commodities. Forward commodity contracts are marked-to-market, with the resulting gains and losses recognized in earnings, in the same category as the items being hedged, when the hedged transaction is recognized. At September 30, 2019 and 2018, we had no financial contracts related to forward commodity agreements.

Interest Rate Risk Management – The Company has entered into two interest rate swap agreements for a total notional amount of $100 million to exchange floating for fixed rate interest payments for our LIBOR-based borrowings. These interest rate swaps had a fair value of zero at inception and were effective November 30, 2018 and July 31, 2019 with respective maturity dates of November 30, 2021 and February 21, 2023. In accordance with FASB Accounting Standards Codification (“ASC”) ASC 815, the Company designated the interest rate swaps as cash flow hedges of floating-rate borrowings. The interest rate swaps convert the Company’s interest rate payments on the first $100 million of variable-rate, 1-month LIBOR-based debt to a fixed interest rate. These interest rate swaps involve the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the interest rate swap without an exchange of the underlying principal amount.

	Liability Derivatives
	September 30, 2019			December 31, 2018
	Balance Sheet Classification	Fair Value		Balance Sheet Classification	Fair Value
Derivatives designated as hedging instruments under ASC 815:
Interest Rate Contracts	Accrued liabilities and Other liabilities	(2,246)		Accrued liabilities and Other liabilities	(833)
Total Derivatives		$	(2,246)		$	(833)

The following table summarizes adjustments related to cash flow hedge included in Cash-flow hedges, in the Condensed Consolidated Statements of Comprehensive Income:

	September 30, 2019
Loss on derivative instruments included in Accumulated other comprehensive income at December 31, 2018	$	(833)
Fair value adjustment	(1,413)
Loss on derivative instruments included in Accumulated other comprehensive income at September 30, 2019	$	(2,246)

At September 30, 2019, the Company expects to reclassify approximately $0.9 million of net losses on derivative instruments from Accumulated other comprehensive income to earnings during the next 12 months due to the payment of variable interest associated with the floating rate debt.

13. Restructuring

On May 2, 2019, the Company approved the closure of its Pottsville, Pennsylvania films plant as part of its broader strategic efforts to improve the Company’s competitive position in providing quality film products and services to its customers. The Company also announced a strategic alliance with Oben Holding Group S.A. (“Oben”), a third-party producer of films for the flexible packaging industry, leveraging the Company's sales channels and Nylon 6 supply with Oben's new state-of-the-art manufacturing facility. The Company ceased operations at the Pottsville, Pennsylvania plant in July 2019.

18

ADVANSIX INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in thousands, except share and per share amounts and as otherwise noted)

Restructuring costs consist of long-lived asset impairments, facility exit costs, employee separations and inventory write-downs. Facility exit costs include demolition, equipment relocation, contract terminations and project management costs. These costs are included in Cost of goods sold in the Condensed Consolidated Statements of Operations. The Company recorded a restructuring charge of $12.6 million in the second quarter of 2019 and does not expect to incur any additional restructuring charges related to the closure of its films plant.

Restructuring costs for the nine months ended September 30, 2019 were as follows:

	Nine Months Ended September 30, 2019
Write-off of equipment and facility	$	7,131
Facility exit costs	2,686
Employee separations	1,364
Inventory write-downs	1,442
Total restructuring charges	$	12,623

The following table summarizes the components of restructuring activities and the remaining balances of accrued restructuring charges as of September 30, 2019:

	Employee Separation Benefits		Facility Exit Costs		Total
Accrual balance at December 31, 2018	$	—	$	—	$	—
Charges	1,364		2,686		4,050
Cash payments	(1,364)		(103)		(1,467)
Accrual balance at September 30, 2019	$	—	$	2,583	$	2,583

The balance of accrued restructuring charges is expected to be settled within the next twelve months.

19

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of the Company’s financial condition and results of operations, which we refer to as our “MD&A,” should be read in conjunction with the Condensed Consolidated Financial Statements and the notes thereto contained elsewhere in this Form 10-Q, as well as the MD&A section included in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission (“SEC”) on February 22, 2019 (the “2018 Form 10-K”). Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a number of factors that can affect our performance in both near- and long-term, including those incorporated by reference in Item 1A of Part II of this Form 10-Q as such factors may be revised or supplemented in subsequent filings with the SEC, as well as those discussed in the section entitled “Note Regarding Forward-Looking Statements” below.

Note Regarding Forward-Looking Statements

All statements other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this MD&A regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this Form 10-Q, words such as “anticipate,” “believe,” “will,” “estimate,” “expect,” “plan,” “intend” and similar expressions identify forward-looking statements. Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties and other factors, many of which are beyond our control and difficult to predict, which may cause the actual results or performance of the company to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: the impact of scheduled turnarounds and significant unplanned downtime and interruptions of production or logistics operations as a result of mechanical issues or other unanticipated events such as fires, severe weather conditions, and natural disasters; price fluctuations and supply of raw materials; our operations requiring substantial capital; general economic and financial conditions in the U.S. and globally; growth rates and cyclicality of the industries we serve including global changes in supply and demand; risks associated with our indebtedness including with respect to restrictive covenants; failure to develop and commercialize new products or technologies; loss of significant customer relationships; adverse trade and tax policies; extensive environmental, health and safety laws that apply to our operations; hazards associated with chemical manufacturing, storage and transportation; litigation associated with chemical manufacturing and our business operations generally; inability to acquire and integrate businesses, assets, products or technologies; protection of our intellectual property and proprietary information; prolonged work stoppages as a result of labor difficulties; cybersecurity and data privacy incidents; failure to maintain effective internal controls; disruptions in transportation and logistics; our inability to achieve some or all of the anticipated benefits of our spin-off including uncertainty regarding qualification for expected tax treatment; fluctuations in our stock price; and changes in laws or regulations applicable to our business. Forward-looking statements are not guarantees of future performance and actual results could differ materially from those contemplated by the forward-looking statements as a result of a number of risks, uncertainties and other factors including those noted above and those detailed in Item 1A of Part I and elsewhere in our 2018 Form 10-K and subsequent filings with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We do not undertake to update or revise any of our forward-looking statements.

Business Overview

We produce and sell caprolactam as a commodity product and produce and sell our Nylon 6 resin as both a commoditized and differentiated resin product. Our results of operations are primarily driven by production volume and the spread between the sales prices of our products and the costs of the underlying raw materials built into market-based and value-based pricing models. The global prices for nylon resin typically track a spread over the price of caprolactam, which in turn tracks as a spread over benzene because the key feedstock materials for caprolactam, phenol or cyclohexane, are derived from benzene. This price spread has historically experienced cyclicality as a result of global changes in supply and demand. Generally, Nylon 6 resin prices track the cyclicality of caprolactam prices, although prices set above the spread are achievable when nylon resin manufacturers, like AdvanSix, formulate and produce differentiated nylon resin products. Our differentiated Nylon 6 products are typically valued at a higher level than commodity resin products.

We believe that the Nylon 6 end-market growth will continue to generally track global GDP over the long-term; applications such as packaging and engineering plastics have potential to grow at faster rates given certain macrotrends. Additionally, one of

20

our strategies is to continue developing higher-value, differentiated Nylon 6 products, such as our co-polymer offerings, in current and new customer applications.

Our ammonium sulfate is used by customers as a fertilizer containing nitrogen and sulfur, two key crop nutrients. Global prices for ammonium sulfate fertilizer are influenced by several factors including the price of urea, which is the most widely used source of nitrogen-based fertilizer in the world. Other global factors driving ammonium sulfate fertilizer demand are general agriculture trends, including the price of crops. Our ammonium sulfate product is positioned with the added value proposition of sulfur nutrition to increase yields of key crops.

We produce ammonium sulfate fertilizer continuously throughout the year as part of our manufacturing process, but quarterly sales experience seasonality based on the timing and length of the growing seasons in North and South America. North America ammonium sulfate prices are typically strongest during second quarter fertilizer application and then typically decline seasonally with new season fill in the third quarter. Due to the ammonium sulfate fertilizer sales cycle, we occasionally build up higher inventory balances because our production is continuous and not tied to seasonal demand for fertilizers. Sales of most of our other products have generally been subject to minimal, or no, seasonality.

We also manufacture, market and sell a number of chemical intermediate products that are derived from the chemical processes within our integrated supply chain. Most significant is acetone, which is used by our customers in the production of adhesives, paints, coatings and solvents. Prices for acetone are influenced by its own supply and demand dynamics but can also be influenced by the underlying move in propylene input costs.

We seek to run our production facilities on a nearly continuous basis for maximum efficiency as several of our intermediate products are key feedstock materials for other products in our integrated manufacturing chain. While our integration, scale and range of product offerings make us one of the most efficient manufacturers in our industry, these attributes also expose us to increased risk associated with material disruptions at any one of our production facilities or logistics operations which could impact the overall manufacturing supply chain. Further, although we believe that our sources of supply for our raw materials, including cumene, natural gas and sulfur, are generally robust, it is difficult to predict the impact that shortages, increased costs and related supply chain logistics considerations may have in the future. In order to mitigate the risk of unplanned interruptions, we schedule several planned plant turnarounds each year to conduct routine and major maintenance across our facilities. We also utilize maintenance excellence and mechanical integrity programs, targeted buffer inventory of intermediate chemicals necessary for our manufacturing process, and co-producer swap arrangements, which are intended to mitigate the extent of any production losses as a result of planned and unplanned downtime; however, the mitigation of all or part of any such production impact cannot be assured.

Recent Developments

On May 2, 2019, the Company approved the closure of its Pottsville, Pennsylvania films plant as part of its broader strategic efforts to improve the Company’s competitive position in providing quality film products and services to its customers. The Company has also announced a strategic alliance with Oben Holdings Group S.A. (“Oben”), a third-party producer of films for the flexible packaging industry, leveraging the Company's sales channels and Nylon 6 resin supply with Oben's new state-of-the-art manufacturing facility. The Company ceased operations at the Pottsville, Pennsylvania plant in July 2019. We recognized a restructuring charge of $12.6 million during the second quarter of 2019 and do not expect to incur any additional restructuring charges related to the closure. See “Note 13. Restructuring” to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q for further information.

On February 19, 2019, the Company announced that it filed anti-dumping duty petitions covering imports of acetone with the International Trade Commission (“ITC”) and U.S. Department of Commerce. The petitions allege that dumped acetone imports into the United States from Belgium, Korea, Saudi Arabia, Singapore, South Africa, and Spain have caused material injury to the domestic industry. On April 4, 2019, the ITC voted to continue the anti-dumping duty investigations concerning imports of acetone from all such nations other than Saudi Arabia. During the third quarter of 2019, the U.S. Department of Commerce announced its preliminary affirmative determination regarding anti-dumping duties for Singapore, Spain, Belgium, South Africa and South Korea. The Company expects the full investigation process to be completed during the first quarter of 2020.

On March 13, 2018, a federal search warrant was executed at the Company’s Hopewell, Virginia manufacturing facility. On the same date, the Company was separately served with a grand jury subpoena issued by the U.S. District Court for the Eastern District of Virginia, which requested documents related to the Hopewell facility’s air emissions and its compliance with the terms of a previously disclosed 2013 consent decree with the federal government and the Commonwealth of Virginia. As previously reported in our 2018 Form 10-K, the Company was notified during the first quarter of 2019 that the U.S. Attorney’s Office for the Eastern District of Virginia had closed its investigation and no further action by the Company was required. On

21

May 13, 2019, the Company announced that the United States government notified the Company that the balance of the criminal investigation concluded with no further action required.

2019 Operational Events

On March 11, 2019, the Company announced that it declared force majeure on its phenol product line as a result of shortages and delivery delays of its key raw material, cumene. The Company's cumene deliveries were reduced due to weather related logistics disruptions in the Gulf Coast area and supplier operational constraints. As a result of this force majeure event, phenol production at the Company's Frankford, Pennsylvania facility and caprolactam production at its Hopewell, Virginia facility were reduced. The Company incurred an approximately $6.9 million unfavorable impact to pre-tax income in the first quarter of 2019, including the unfavorable impact of fixed cost absorption and incremental logistics costs. In addition, the Company incurred an approximately $1.4 million unfavorable impact to pre-tax income in the first quarter of 2019 and an approximately $2.3 million unfavorable impact to pre-tax income in the second quarter of 2019 due to lost sales. The Company is no longer on force majeure with phenol customers.

On June 24, 2019, the Company announced that it was assessing the potential business impact of the fire that occurred at Philadelphia Energy Solutions' (“PES”) refinery in Philadelphia. PES is one of multiple suppliers to the Company of cumene, a feedstock material used to produce phenol, acetone and other chemical intermediates. The Company continues to operate its facilities while implementing its mitigation plans, including evaluation of business interruption insurance. The PES fire did not have a material impact on second quarter 2019 financial results. The Company incurred an approximately $4.3 million unfavorable impact to pre-tax income in the third quarter of 2019 and anticipates an approximately $4 to $6 million unfavorable impact to pre-tax income in the fourth quarter of 2019, including incremental raw material and logistics costs as well as a modest unfavorable impact from fixed cost absorption. The Company continues to assess long-term optionality for cumene supply and logistics, while optimizing expected base feedstock and logistics cost increases as it realigns its supply chain into 2020. The Company anticipates an approximately $10 to $15 million unfavorable impact to pre-tax income in 2020.

2018 Operational Events

On January 17, 2018, the Company announced that it had experienced a temporary production issue at its Hopewell, Virginia facility related to the severe winter weather. As a result of this unplanned interruption, caprolactam and resin production had been reduced at the Hopewell and Chesterfield, Virginia facilities. The Company incurred a $20 million unfavorable impact to pre-tax income in the first quarter of 2018 including the impact of fixed cost absorption, maintenance expense and incremental raw material costs. In addition, the Company incurred an approximately $10 million unfavorable impact to pre-tax income in the first quarter of 2018 due to lost sales. The Company submitted a business interruption insurance claim related to the first quarter 2018 weather event and recorded a benefit of $6.6 million and $2.3 million to Cost of goods sold in the first and second quarters of 2019, respectively. The business interruption claim was closed in the second quarter of 2019 with a total recorded benefit of approximately $12 million.

Results of Operations

(Dollars in thousands, unless otherwise noted)

Sales

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Sales	$	310,633	$	368,653	$	970,743	$	1,128,350
% change compared with prior year period	(15.7)%				(14.0)%

The change in sales compared to the prior year period is attributable to the following:

	Three Months Ended September 30, 2019	Nine Months Ended September 30, 2019
Volume	(2.1)%	(3.6)%
Price	(13.6)%	(10.4)%
	(15.7)%	(14.0)%

22

Sales decreased in the three months ended September 30, 2019 compared to the prior year period by $58.0 million (approximately 16%) due primarily to lower sales prices (approximately 14%) driven by formula-based pass-through pricing (approximately 11% unfavorable impact), particularly for benzene and propylene (inputs to cumene which is a key feedstock material for our products) and market-based pricing decreases (approximately 3% unfavorable impact) in acetone and nylon. Volume decreased by approximately 2% due to unfavorable mix across our nylon and ammonium sulfate product lines, driven in part by operational performance, and continued challenging industry conditions in chemical intermediates, partially offset by improved caprolactam volume due to stronger utilization rates and the larger planned plant turnaround in the prior year period.

Sales decreased in the nine months ended September 30, 2019 compared to the prior year period by $157.6 million (approximately 14%) due primarily to lower sales prices (approximately 10%) driven by formula-based pass-through pricing, particularly for benzene and propylene. Market-based pricing was nearly flat due primarily to increases in ammonium sulfate offset by decreases in acetone. Volume decreased by approximately 4% due primarily to the phenol force majeure discussed above, challenging acetone industry conditions, unfavorable mix across our nylon and ammonium sulfate product lines, driven in part by operational performance, partially offset by improved caprolactam volume due to stronger utilization rates and the larger planned plant turnaround in the prior period.

Costs of Goods Sold

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Costs of goods sold	$	280,123	$	343,434	$	850,131	$	1,007,712
% change compared with prior year period	(18.4)%				(15.6)%
Gross Margin percentage	9.8%		6.8%		12.4%		10.7%

Costs of goods sold decreased in the three months ended September 30, 2019 compared to the prior year period by $63.3 million (approximately 18%) due primarily to (i) lower prices of raw materials, particularly benzene and propylene (approximately 14%) and (ii) higher spend in the prior year driven by the larger planned plant turnaround in the third quarter of 2018 (approximately 7%). These decreases were partially offset by (i) the impact of operational performance in the third quarter of 2019, including fixed cost absorption and unfavorable product mix (approximately 2%) and (ii) the PES cumene supply impact discussed above (approximately 1%).

Costs of goods sold decreased in the nine months ended September 30, 2019 compared to the prior year period by $157.6 million (approximately 16%) due primarily to (i) lower prices of raw materials, particularly benzene and propylene (approximately 13%), (ii) higher spend in the prior year driven by the timing of planned plant turnarounds (approximately 3%), and (iii) lower manufacturing costs versus higher spend in the prior year as a result of the first quarter 2018 weather event, including purchases of feedstocks which are normally manufactured by the Company (approximately 2%), partially offset by the restructuring charge associated with the closure of our Pottsville films plant (approximately 1%).

Gross margin percentage increased by approximately 3% in the three months ended September 30, 2019 compared to the prior year period due primarily to higher spend in the prior year driven by the larger planned plant turnaround in the third quarter of 2018 (approximately 8%), partially offset by (i) the impact of operational performance, including fixed cost absorption and unfavorable mix across product lines (approximately 4%) and (ii) the PES cumene supply impact discussed above (approximately 1%). The impact of formula pass-through pricing and market pricing had approximately a net neutral impact on gross margin percentage.

Gross margin percentage increased by approximately 2% in the nine months ended September 30, 2019 compared to the prior year period due to (i) higher spend in the prior year driven by the timing of planned plant turnarounds (approximately 3%), (ii) the favorable impact of lower raw material pricing (approximately 2%) and (iii) lower manufacturing costs versus the impact of the first quarter 2018 weather event (approximately 2%), partially offset by (i) lower sales volume related to challenging industry conditions and phenol force majeure (approximately 4%) and (ii) Pottsville restructuring charge (approximately 1%).

Selling, General and Administrative Expenses

23

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Selling, general and administrative expenses	$	19,261	$	18,057	$	58,683	$	55,189
Percent of sales	6.2%		4.9%		6.0%		4.9%

Selling, general and administrative expenses increased by $1.2 million in the three months ended September 30, 2019 compared to the prior period due primarily to the timing of IT costs as well as higher legal costs driven by the anti-dumping duty petitions.

Selling, general and administrative expenses increased by $3.5 million in the nine months ended September 30, 2019 compared to the prior period due primarily to the timing of IT costs as well as higher legal costs driven by the anti-dumping duty petitions, partially offset by lower costs associated with the exit of Honeywell transition services in 2018.

Tax Expense

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Tax expense	$	1,513	$	229	$	13,617	$	13,385
Effective tax rate	16.0%		4.0%		23.9%		22.7%

The Company’s effective tax rate for the three months ended September 30, 2019 was lower compared to the U.S. federal statutory rate, due primarily to additional research tax credits claimed on the Company's 2018 U.S. federal income tax return affecting the current period results, partially offset by state taxes and executive compensation deduction limitations. The Company’s effective tax rate for the three months ended September 30, 2018 was lower compared to the U.S. federal statutory rate, due primarily to the accounting under ASC 740 for the Tax Act and adjustments resulting from the filing of the 2017 U.S. federal income tax return, partially offset by state taxes. The Company’s effective tax rate for the nine months ended September 30, 2019 and 2018 was higher compared to the U.S. federal statutory rate due primarily to state taxes and executive compensation deduction limitations partially offset by research tax credits and tax benefits associated with return-to-provision adjustments.

The Company’s effective tax rate for the three months ended September 30, 2019 was higher than the prior year due primarily to the tax benefit associated with accounting under ASC 740 (Staff Accounting Bulletin No 118) for the Tax Act recorded in the period ended September 30, 2018. The Company’s effective tax rate for the nine months ended September 30, 2019 was higher than the prior year due primarily to an increase in expected non-deductible executive compensation amounts, and a decrease in the benefits from the vesting of restricted stock units, partially offset by additional research tax credits referenced above (see Note 10. Income Taxes).

Net Income

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Net income	$	7,921	$	5,480	$	43,441	$	45,483

As a result of the factors described above, Net income was $7.9 million and $43.4 million for the three and nine months ended September 30, 2019 as compared to $5.5 million and $45.5 million in the corresponding prior year period.

Non-GAAP Measures

(Dollars in thousands, unless otherwise noted)

The following tables set forth the non-GAAP financial measures of EBITDA and EBITDA Margin, and EBITDA and EBITDA Margin excluding the one-time Pottsville restructuring charges described below. EBITDA is defined as Net income before Interest, Income taxes and Depreciation and amortization. EBITDA Margin is equal to EBITDA divided by Sales. The Company believes these non-GAAP financial measures provide meaningful supplemental information as they are used by the

24

Company’s management to evaluate the Company’s operating performance, enhance a reader’s understanding of the financial performance of the Company, and facilitate a better comparison among fiscal periods and performance relative to its competitors, as the non-GAAP measures exclude items that are not considered core to the Company’s operations.

These non-GAAP results are presented for supplemental informational purposes only and should not be considered a substitute for the financial information presented in accordance with GAAP. Non-GAAP financial measures should be read only in conjunction with the comparable GAAP financial measures. The Company's non-GAAP measures may not be comparable to other companies' non-GAAP measures.

The following is a reconciliation between the non-GAAP financial measures of EBITDA and EBITDA Margin, and EBITDA and EBITDA Margin excluding the one-time Pottsville restructuring charges, to their most directly comparable GAAP financial measure:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Net income	$	7,921	$	5,480	$	43,441	$	45,483
Interest expense, net	1,293		1,270		3,727		5,958
Income taxes	1,513		229		13,617		13,385
Depreciation and amortization	14,222		12,992		42,094		38,905
EBITDA (non-GAAP)	24,949		19,971		102,879		103,731
One-time Pottsville restructuring charges (1)	—		—		12,623		—
EBITDA excluding one-time Pottsville restructuring charges (non-GAAP)	$	24,949	$	19,971	$	115,502	$	103,731
Sales	$	310,633	$	368,653	$	970,743	$	1,128,350
EBITDA margin (non-GAAP)	8.0%		5.4%		10.6%		9.2%
EBITDA margin excluding one-time Pottsville restructuring charges (non-GAAP)	8.0%		5.4%		11.9%		9.2%

(1) Current year one-time Pottsville restructuring charges reflect the closure of the Company's Pottsville, Pennsylvania films plant. See “Note 13. Restructuring” to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q for further information.

Liquidity and Capital Resources

(Dollars in thousands, unless otherwise noted)

We believe that cash balances and operating cash flows, together with available capacity under our credit agreement, will provide adequate funds to support our current short-term operating objectives as well as our longer-term strategic plans, subject to the risks and uncertainties outlined below, in our "Note Regarding Forward-Looking Statements" above, and in the risk factors previously disclosed in our 2018 Form 10-K. Our principal source of liquidity is our cash flow generated from operating activities, which is expected to provide us with the ability to meet the majority of our short-term funding requirements. Our cash flows are affected by capital requirements and production volume, which may be materially impacted by unanticipated events such as unplanned downtime, material disruptions at our production facilities as well as the prices of our raw materials and general economic and industry trends. We utilize supply chain financing and trade receivables discount arrangements with third-party financial institutions which enhance liquidity and enable us to efficiently manage our working capital needs. In addition, we monitor the third-party depository institutions that hold our cash and cash equivalents. Our emphasis is primarily on the safety of principal and secondarily on maximizing yield on those funds. We diversify our cash and cash equivalents among counterparties to minimize exposure to any one of these entities.

On a recurring basis, our primary future cash needs will be centered on operating activities, working capital, capital expenditures including high return growth and cost savings investments, share repurchases, employee benefit obligations, interest payments, strategic acquisitions and debt management. We believe that our future cash from operations, together with cash on hand and our access to credit and capital markets, will provide adequate resources to fund our expected operating and

25

financing needs. Our ability to fund our capital needs, however, will depend on our ongoing ability to generate cash from operations and access to credit and capital markets, both of which are subject to the risk factors previously disclosed in our 2018 Form 10-K, as well as general economic, financial, competitive, regulatory and other factors that are beyond our control.

We assumed from Honeywell all health, safety and environmental (“HSE”) liabilities and compliance obligations related to the past and future operations of our current business, as well as all HSE liabilities associated with our three current manufacturing locations and the other locations used in our current operations including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to be material for 2019.

We expect that our primary cash requirements for the remainder of 2019 will be to fund costs associated with ongoing operations, capital expenditures, share repurchases and amounts related to other contractual obligations.

The Company made contributions to the defined benefit pension plan of $4.2 million during the nine months ended September 30, 2019 sufficient to satisfy pension funding requirements for 2019 under the AdvanSix Retirement Earnings Plan. The Company made contributions of $0 in the first quarter of 2019, $0.5 million in the second quarter of 2019 and $3.7 million in the third quarter of 2019. The Company does not plan to make pension plan contributions during the fourth quarter of 2019, but plans to make additional contributions in future years sufficient to satisfy pension funding requirements in those periods.

On May 4, 2018, the Company announced that its Board of Directors (the “Board”) authorized a share repurchase program of up to $75 million of the Company’s common stock. On February 22, 2019, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company’s common stock, which was in addition to the remaining capacity available under the May 2018 share repurchase program. Repurchases may be made from time to time on the open market, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The repurchase program has no expiration date and may be modified, suspended or discontinued at any time.

As of September 30, 2019, the Company had repurchased 3,089,762 shares of common stock for an aggregate of $90.4 million at a weighted average market price of $29.26 per share. As of September 30, 2019, $59.6 million remained available for repurchase under the current authorization. During the period from October 1, 2019 through October 25, 2019, no additional shares were repurchased under the currently authorized repurchase program. On October 3, 2019, the Company withheld 388,530 shares covering tax withholding obligations in connection with the vesting of founders' grant equity awards for an aggregate purchase amount of approximately $9.1 million, reducing the number of shares outstanding.

Credit Agreement

On February 21, 2018 (the “Amendment Date”), the Company entered into Amendment No. 1 (the “Amendment”) to the Credit Agreement, dated September 30, 2016 (the “Original Credit Agreement”), among the Company, the guarantors, the lenders party thereto and Bank of America, N.A., as administrative agent (the Original Credit Agreement, after giving effect to the Amendment, the “Amended and Restated Credit Agreement”).

The credit facilities under the Original Credit Agreement consisted of a senior secured term loan in an aggregate principal amount of $270 million, of which $267 million was outstanding just prior to entering into the Amendment, and a senior secured revolving credit facility in a principal amount of $155 million. Pursuant to the Amendment, (i) the term loan facility under the Original Credit Agreement was terminated and the entire outstanding balance of the term loan facility (the “Term Loan”) thereunder was paid in full, and (ii) the maximum aggregate principal amount of the senior secured revolving credit facility (the “Revolving Credit Facility”) was increased to $425 million.

On the Amendment Date, the Company borrowed $242 million under the Revolving Credit Facility. The proceeds of such loans, as well as cash on hand, were used to repay the outstanding Term Loan under the Original Credit Agreement. The Revolving Credit Facility under the Amended and Restated Credit Agreement has a 5-year term with a scheduled maturity date of February 21, 2023. The Amendment resulted in an increase in the Revolving Credit Facility to replace the Term Loan and provides increased borrowing flexibility and reduced overall borrowing costs with an approximate 50 basis point reduction in the interest rate spread.

26

The Amended and Restated Credit Agreement contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, pay cash dividends, incur debt or liens, redeem or repurchase stock of the Company, enter into transactions with affiliates, make investments, make capital expenditures, merge or consolidate with others or dispose of assets, as well as financial covenants that require the Company to maintain interest coverage and leverage ratios at levels specified in the Amended and Restated Credit Agreement. These covenants may limit how we conduct our business, and in the event of certain defaults, our repayment obligations may be accelerated. We were in compliance with all of our covenants at September 30, 2019. As of September 30, 2019, $158 million is available for use out of the total of $425 million under the Revolving Credit Facility.

As of December 31, 2018, we had a balance of $200 million under the Revolving Credit Facility. During the first nine months of 2019, we borrowed an incremental net amount of $66 million to bring the balance under the Revolving Credit Facility to $266 million as of September 30, 2019. Going forward, we expect that cash provided by operating activities will fund future interest payments on the Company's outstanding indebtedness.

Cash Flow Summary

	Nine Months Ended September 30,
	2019		2018
Cash provided by (used for):
Operating activities	$	100,536	$	127,735
Investing activities	(108,589)		(74,306)
Financing activities	8,293		(88,655)
Net change in cash and cash equivalents	$	240	$	(35,226)

Cash provided by operating activities decreased by $27.2 million for the nine months ended September 30, 2019 versus the prior year period due primarily to a $9.1 million reduction in cash flow from working capital (comprised of Accounts receivables, Inventories, Accounts payable and Deferred income and customer advances) for the first nine months ended September 30, 2019 versus a $35.5 million improvement in the prior year period, partially offset by a favorable impact from the timing of cash payments on Accrued liabilities of $5.2 million versus the prior year period. The Pottsville restructuring charge had a minor impact on operational cash flows for the nine months ended September 30, 2019. See “Note 13. Restructuring” to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q for further information.

Cash used for investing activities increased by $34.3 million for the nine months ended September 30, 2019 versus the prior year period due to an increase in cash paid for capital expenditures.

Cash provided by financing activities increased by $96.9 million for the nine months ended September 30, 2019 versus the prior year period due to net borrowings of $66.0 million for the nine months ended September 30, 2019 compared to net repayments of $66.6 million during the prior year period, offset by $53.1 million in cash outflows for share repurchases during the nine months ended September 30, 2019 compared to $20.4 million in cash outflows during the prior year period, both of which are described above.

Capital Expenditures

(Dollars in thousands, unless otherwise noted)

Our operations are capital intensive, requiring ongoing investments that have consisted, and are expected to continue to consist, primarily of capital expenditures required to maintain and improve equipment reliability, expand production output, further improve mix, yield and cost position, and comply with environmental and safety regulations.

The following table summarizes ongoing and expansion capital expenditures:

27

	Nine Months Ended September 30, 2019
Capital expenditures in Accounts payable at December 31, 2018	$	27,258
Purchases of property, plant and equipment	106,472
Less: Capital expenditures in Accounts payable at September 30, 2019	(27,344)
Cash paid for capital expenditures	$	106,386

For the full year 2019, we expect the Company’s cash paid for capital expenditures to be approximately $150 million.

Critical Accounting Policies

The preparation of our Condensed Consolidated Financial Statements in accordance with U.S. GAAP is based on the selection and application of accounting policies that require us to make significant estimates and assumptions about the effects of matters that are inherently uncertain. We consider these accounting policies to be critical to the understanding of our Condensed Consolidated Financial Statements. For a full description of our critical accounting policies, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our 2018 Form 10-K. While there have been no material changes to our critical accounting policies, or the methodologies or assumptions we apply under them, during the first quarter of 2019, as described in “Note 2. Recent Accounting Pronouncements,” the Company changed the manner in which it accounts for leases under guidance that became effective January 1, 2019.

Off-Balance Sheet Arrangements and Contractual Obligations

As of September 30, 2019, the Company did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any material changes in the commitments or contractual obligations detailed in the Company's 2018 Form 10-K. The Company has not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.

Recent Accounting Pronouncements

See “Note 2. Recent Accounting Pronouncements” to the Condensed Consolidated Financial Statements included in Part I. Item 1 of this Form 10-Q.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

Our exposure to risk based on changes in interest rates relates primarily to our Amended and Restated Credit Agreement. The Amended and Restated Credit Agreement bears interest at floating rates. For variable rate debt, interest rate changes generally do not affect the fair market value of such debt assuming all other factors remain constant, but do impact future earnings and cash flows. Accordingly, we may be exposed to interest rate risk on borrowings under the Amended and Restated Credit Agreement.

The Company has entered into two interest rate swap agreements for a total notional amount of $100 million to exchange floating for fixed rate interest payments for our LIBOR-based borrowings.

These interest rate swaps had a fair value of zero at inception, were effective November 30, 2018 and July 31, 2019 with respective maturity dates of November 30, 2021 and February 21, 2023. These interest rate swaps have been designated as cash flow hedges and convert the Company’s interest rate payments on the first $100 million of variable-rate, 1-month LIBOR-based debt to a fixed interest rate. As a result of these interest rate swaps, approximately 38% of our total borrowings as of September 30, 2019 are at a fixed interest rate. These interest rate swaps involve the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the swaps without an exchange of the underlying principal amount.

A hedge effectiveness assessment was completed by comparing the critical terms of the hedged items with the hedging instruments, and also by reviewing the credit standing of the counterparties. As of September 30, 2019, it was determined that the critical terms continued to exactly match, and that the counterparties still had the ability to honor their obligations. As a result, the hedges continue to be deemed effective.

28

Based on current borrowing levels at September 30, 2019, net of the interest rate swap, a 25-basis point fluctuation in interest rates for the nine months ended September 30, 2019 would have resulted in an increase or decrease to our interest expense of approximately $0.4 million.

See “Note 12. Derivative and Hedging Instruments” to the Condensed Consolidated Financial Statements, included in Part I. Item 1 of this Form 10-Q, for a discussion relating to credit and market, commodity price and interest rate risk.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed or submitted under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud have been, or will be, detected.

Our Chief Executive Officer and Chief Financial Officer, with the assistance of other members of our management, conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective at a reasonable assurance level as of September 30, 2019, the end of the period covered by this quarterly report.

Changes in Internal Control over Financial Reporting

Management has not identified any change in the Company's internal control over financial reporting that occurred during the quarter ended September 30, 2019 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we are involved in litigation relating to claims arising outside of the ordinary course of our business operations. We are not a party to, and, to our knowledge, there are not threats of any claims or actions against us, the ultimate disposition of which would have a material adverse effect on our consolidated financial position, results of operations or operating cash flows.

ITEM 1A. RISK FACTORS

There have been no material changes to our risk factors as previously disclosed in Item 1A of Part I of the Company’s 2018 Form 10-K, which are hereby incorporated by reference.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On May 4, 2018, the Company announced that the Board authorized a share repurchase program of up to $75 million of the Company’s common stock. On February 22, 2019, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which authorization was in addition to the remaining capacity authorized under the May 2018 share repurchase program. Repurchases may be made from time to time on the open market, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time.

29

The below table sets forth the repurchases of Company common stock, by month, for the quarter ended September 30, 2019:

ISSUER PURCHASES OF EQUITY SECURITIES

Period		Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plan	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan
July 2019	(1)	226,011	$	24.96	223,027	$	66,730,746
August 2019		242,699	22.95		242,699	61,160,234
September 2019		68,323	23.10		68,323	59,581,679
Total		537,033	$	23.82	534,049

(1) Total number of shares purchased includes 2,984 shares withheld to cover tax withholding obligations in connection with the vesting of equity awards.

During the period from October 1, 2019 through October 25, 2019, no additional shares were repurchased under the currently authorized repurchase program. On October 3, 2019, the Company withheld 388,530 shares covering tax withholding obligations in connection with the vesting of founders’ grant equity awards for an aggregate purchase amount of approximately $9.1 million, reducing the number of shares outstanding.

30

ITEM 6. EXHIBITS 

Exhibit	Description
3.1	Amended and Restated Certificate of Incorporation of AdvanSix Inc. (conformed copy)
3.2	Amended and Restated By-laws of AdvanSix Inc.
31.1	Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Executive Officer.
31.2	Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Financial Officer.
32.1	Section 1350 Certification of the Company’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
32.2	Section 1350 Certification of the Company’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
101.INS	Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101)

31

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ADVANSIX INC.
Date: November 1, 2019	By:	/s/ Michael Preston
		Michael Preston
		Senior Vice President and Chief Financial Officer

32

EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Erin N. Kane, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of AdvanSix Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2019

/s/ Erin N. Kane

Erin N. Kane

President and Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Michael Preston, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of AdvanSix Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2019

/s/ Michael Preston

Michael Preston

Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AdvanSix Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:  November 1, 2019

/s/ Erin N. Kane

Erin N. Kane

President and Chief Executive Officer

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AdvanSix Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 1, 2019

/s/ Michael Preston

Michael Preston

Chief Financial Officer

XML

Revenues

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Revenues

Revenues

Revenue Recognition

We serve approximately 400 customers annually in more than 40 countries and across a wide variety of industries. For the three months ended September 30, 2019 and 2018, the Company's ten largest customers accounted for approximately 51% and 48% of total sales, respectively. For the nine months ended September 30, 2019 and 2018, the Company's ten largest customers accounted for approximately 47% and 45% of total sales, respectively.

We typically sell to customers under master service agreements, with one- to two-year terms on average, or by purchase orders. We have historically experienced low customer turnover and have an average customer relationship of approximately 20 years. Our largest customer is Shaw Industries Group Inc. (“Shaw”), one of the world's largest consumers of caprolactam and Nylon 6 resin. We sell Nylon 6 resin and caprolactam to Shaw under a long-term agreement. For the three months ended September 30, 2019 and 2018, our sales to Shaw were 23% and 22%, respectively, of our total sales. For the nine months ended September 30, 2019 and 2018, our sales to Shaw were 21% and 22%, respectively, of our total sales.

Each of the Company’s product lines represented the following approximate percentage of total sales for the three and nine months ended September 30, 2019 and 2018:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019	2018
Nylon	25%	28%	28%	28%
Caprolactam	26%	18%	22%	18%
Ammonium Sulfate Fertilizers	20%	19%	23%	20%
Chemical Intermediates	29%	35%	27%	34%
	100%	100%	100%	100%

The Company's revenues by geographic area for the three and nine months ended September 30, 2019 and 2018 were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	250,056	$	306,050	$	797,249	$	946,195
International	60,577		62,603		173,494		182,155
Total	$	310,633	$	368,653	$	970,743	$	1,128,350

Deferred Income and Customer Advances

The Company defers revenues when cash payments are received in advance of our performance. Customer advances relate primarily to sales from the ammonium sulfate business. Below is a roll-forward of Deferred income and customer advances for the nine months ended September 30, 2019:

Opening balance January 1, 2019	$	22,556
Additions to deferred revenues	1,083
Less amounts recognized in revenues	(21,691)
Ending balance September 30, 2019	$	1,948

The Company expects to recognize as revenue the September 30, 2019 ending balance of Deferred income and customer advances within one year or less.

XML

Postretirement Benefit Cost

9 Months Ended

Sep. 30, 2019

Retirement Benefits [Abstract]

Postretirement Benefit Cost

Postretirement Benefit Cost

The components of Net periodic benefit cost of the Company’s pension plan are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Service cost	$	1,714	$	2,001	$	5,141	$	6,004
Interest cost	521		469		1,563		1,407
Expected return on plan assets	(334)		(287)		(1,002)		(862)
Net periodic benefit cost	$	1,901	$	2,183	$	5,702	$	6,549

The Company made contributions to the defined benefit pension plan of $4.2 million during the nine months ended September 30, 2019 sufficient to satisfy pension funding requirements for 2019 under the AdvanSix Retirement Earnings Plan. The Company made contributions of $0 in the first quarter of 2019, $0.5 million in the second quarter of 2019 and $3.7 million in the third quarter of 2019. The Company does not plan to make additional pension plan contributions during the fourth quarter of 2019, but plans to make additional contributions in future years sufficient to satisfy pension funding requirements in those periods.

The pension plan assets are invested through a master trust fund. The strategic asset allocation for the trust fund is selected by the Company's Investment Committee reflecting the results of comprehensive asset and liability modeling. The Investment Committee establishes strategic asset allocation percentage targets and appropriate benchmarks for significant asset classes with the aim of achieving a prudent balance between return and risk.

XML

Fair Value Measurements

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements

Financial and non-financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. During the fourth quarter of 2018, the Company acquired a royalty stream which has been treated as an asset acquisition. The purchase price of the royalty stream for $1.0 million approximated its fair value at December 31, 2018 and is considered a Level 3 asset. The fair value measurement is based on the expected future cash flows and, as there is no reason to believe that the asset is impaired, it is assumed that the valuation remains unchanged at September 30, 2019. In November 2018 and July 2019, the Company entered into two interest rate swap transactions related to its credit agreement. The fair value of the interest rate swaps at September 30, 2019 was a loss of approximately $2.2 million and is considered a Level 2 liability.

The pension plan assets are invested in collective investment trust funds. These investments are measured at fair value using the net asset value per share as a practical expedient. Investments valued using the net asset value method (NAV) (or its equivalent) practical expedient are excluded from the fair value hierarchy disclosure.

The Company’s Condensed Consolidated Balance Sheets also include Cash and cash equivalents, Accounts receivable and Accounts payable all of which are recorded at amounts which approximate fair value.

The Company also has assets that are required to be recorded at fair value on a non-recurring basis. These assets are evaluated when certain triggering events occur (including a decrease in estimated future cash flows) that indicate the asset should be evaluated for impairment. Goodwill and indefinite lived intangible assets must be evaluated at least annually.

XML

Earnings Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Basic
Net Income	$ 7,921	$ 15,346	$ 20,174	$ 5,480	$ 28,410	$ 11,593	$ 43,441	$ 45,483
Weighted average common shares outstanding (in shares)	27,608,985			30,160,991			28,192,760	30,375,873
EPS – Basic (in dollars per share)	$ 0.29			$ 0.18			$ 1.54	$ 1.50
Diluted
Dilutive effect of equity awards and other stock-based holdings (in shares)	972,466			822,843			971,264	813,767
Weighted average common shares outstanding (in shares)	28,581,451			30,983,834			29,164,024	31,189,640
EPS – Diluted (in dollars per share)	$ 0.28			$ 0.18			$ 1.49	$ 1.46

XML

Organization, Operations and Basis of Presentation (Details) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended	12 Months Ended	17 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2019	Feb. 22, 2019	May 04, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Liabilities to creditors, payments issued but outstanding				$ 5,400,000	$ 7,700,000
Share repurchase program, maximum amount of shares authorized to be repurchased							$ 75,000,000	$ 75,000,000
Stock repurchased during period (in shares)						3,089,762
Stock repurchased during period, value						$ 90,400,000
Treasury stock acquired, weighted average cost per share (in dollars per share)						$ 29.26
Stock repurchase program, remaining authorized repurchase amount				$ 59,600,000		$ 59,600,000
Cost of Sales
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Insurance recoveries	$ 2,300,000	$ 6,600,000	$ 12,000,000

XML

Derivative and Hedging Instruments - Balance Sheet Classification (Details) - Designated as Hedging Instrument - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Derivative [Line Items]
Derivative liability, fair value	$ (2,246)	$ (833)
Interest Rate Contracts
Derivative [Line Items]
Derivative liability, fair value	$ (2,246)	$ (833)

XML

Leases - Cumulative Effect of Adoption of New Leasing Standard (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
ASSETS
Property, plant and equipment - net			$ 1,032
Property, plant and equipment – net	$ 1,427	$ 1,032
Operating lease right-of-use assets	136,122	117,921	0
Total assets	1,211,817	1,152,547	1,034,626
Current liabilities:
Accounts payable		318	318
Operating lease liabilities – short-term	35,656	24,794	0
Total current liabilities	286,668	309,518	284,724
Operating lease liabilities – long-term	100,752	93,127	0
Other liabilities		762	762
Total liabilities	794,591	732,209	614,288
Total equity		420,338	420,338
Total liabilities and equity	$ 1,211,817	1,152,547	$ 1,034,626
Accounting Standards Update 2016-02
ASSETS
Property, plant and equipment – net		0
Operating lease right-of-use assets		117,921
Total assets		117,921
Current liabilities:
Accounts payable		0
Operating lease liabilities – short-term		24,794
Total current liabilities		24,794
Operating lease liabilities – long-term		93,127
Other liabilities		0
Total liabilities		117,921
Total equity		0
Total liabilities and equity		$ 117,921

XML

Leases - Narrative (Details)	Sep. 30, 2019
Leases [Abstract]
Leases, term of contract	20 years

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Treasury Stock	Accumulated  Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2017		30,482,966
Beginning balance at Dec. 31, 2017	$ 376,325	$ 305	$ 263,081	$ 121,985	$ 0	$ (9,046)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income	11,593			11,593
Comprehensive income
Foreign exchange translation adjustments	(1)					(1)
Cash-flow Hedges	0
Pension obligation adjustments	0			(410)		410
Other comprehensive income (loss), net of tax	(1)			(410)		409
Issuance of common stock (in shares)		25,356
Issuance of common stock	0
Purchase of treasury shares	(370)		(370)
Stock-based compensation	2,281		2,281
Ending balance (in shares) at Mar. 31, 2018		30,508,322
Ending balance at Mar. 31, 2018	389,828	$ 305	264,992	133,168	0	(8,637)
Beginning balance (in shares) at Dec. 31, 2017		30,482,966
Beginning balance at Dec. 31, 2017	376,325	$ 305	263,081	121,985	0	(9,046)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income	45,483
Comprehensive income
Cash-flow Hedges	0
Ending balance (in shares) at Sep. 30, 2018		30,555,715
Ending balance at Sep. 30, 2018	408,845	$ 306	250,149	167,058	(6)	(8,662)
Beginning balance (in shares) at Mar. 31, 2018		30,508,322
Beginning balance at Mar. 31, 2018	389,828	$ 305	264,992	133,168	0	(8,637)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income	28,410			28,410
Comprehensive income
Foreign exchange translation adjustments	(17)					(17)
Cash-flow Hedges	0
Pension obligation adjustments	0
Other comprehensive income (loss), net of tax	(17)					(17)
Issuance of common stock (in shares)		16,416
Issuance of common stock	0
Purchase of treasury shares	(2,743)		(2,742)		(1)
Stock-based compensation	2,599		2,599
Ending balance (in shares) at Jun. 30, 2018		30,524,738
Ending balance at Jun. 30, 2018	418,077	$ 305	264,849	161,578	(1)	(8,654)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income	5,480			5,480
Comprehensive income
Foreign exchange translation adjustments	(8)					(8)
Cash-flow Hedges	0
Pension obligation adjustments	0
Other comprehensive income (loss), net of tax	(8)					(8)
Issuance of common stock (in shares)		30,977
Issuance of common stock	1	$ 1
Purchase of treasury shares	(17,331)		(17,326)		(5)
Stock-based compensation	2,626		2,626
Ending balance (in shares) at Sep. 30, 2018		30,555,715
Ending balance at Sep. 30, 2018	$ 408,845	$ 306	250,149	167,058	(6)	(8,662)
Beginning balance (in shares) at Dec. 31, 2018	29,345,001	30,555,715
Beginning balance at Dec. 31, 2018	$ 420,338	$ 306	234,699	187,819	(12)	(2,474)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income	20,174			20,174
Comprehensive income
Foreign exchange translation adjustments	(1)					(1)
Cash-flow Hedges	(192)					(192)
Pension obligation adjustments	0
Other comprehensive income (loss), net of tax	(193)					(193)
Issuance of common stock (in shares)		22,497
Issuance of common stock	16		16
Purchase of treasury shares	(23,853)		(23,845)		(8)
Stock-based compensation	2,762		2,762
Ending balance (in shares) at Mar. 31, 2019		30,578,212
Ending balance at Mar. 31, 2019	$ 419,244	$ 306	213,632	207,993	(20)	(2,667)
Beginning balance (in shares) at Dec. 31, 2018	29,345,001	30,555,715
Beginning balance at Dec. 31, 2018	$ 420,338	$ 306	234,699	187,819	(12)	(2,474)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income	43,441
Comprehensive income
Cash-flow Hedges	$ (1,060)
Ending balance (in shares) at Sep. 30, 2019	27,481,162	30,600,708
Ending balance at Sep. 30, 2019	$ 417,226	$ 306	189,242	231,260	(31)	(3,551)
Beginning balance (in shares) at Mar. 31, 2019		30,578,212
Beginning balance at Mar. 31, 2019	419,244	$ 306	213,632	207,993	(20)	(2,667)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income	15,346			15,346
Comprehensive income
Foreign exchange translation adjustments	4					4
Cash-flow Hedges	(429)					(429)
Pension obligation adjustments	0
Other comprehensive income (loss), net of tax	(425)					(425)
Issuance of common stock (in shares)		13,260
Issuance of common stock	0
Purchase of treasury shares	(16,414)		(16,408)		(6)
Stock-based compensation	2,812		2,812
Ending balance (in shares) at Jun. 30, 2019		30,591,472
Ending balance at Jun. 30, 2019	420,563	$ 306	200,036	223,339	(26)	(3,092)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income	7,921			7,921
Comprehensive income
Foreign exchange translation adjustments	(20)					(20)
Cash-flow Hedges	(439)					(439)
Pension obligation adjustments	0
Other comprehensive income (loss), net of tax	(459)					(459)
Issuance of common stock (in shares)		9,236
Issuance of common stock	0
Purchase of treasury shares	(12,800)		(12,795)		(5)
Stock-based compensation	$ 2,001		2,001
Ending balance (in shares) at Sep. 30, 2019	27,481,162	30,600,708
Ending balance at Sep. 30, 2019	$ 417,226	$ 306	$ 189,242	$ 231,260	$ (31)	$ (3,551)

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 7,921	$ 5,480	$ 43,441	$ 45,483
Foreign exchange translation adjustment	(20)	(8)	(17)	(26)
Cash-flow hedges	(439)	0	(1,060)	0
Pension obligation adjustments	0	0	0	410
Other comprehensive income (loss), net of tax	(459)	(8)	(1,077)	384
Comprehensive income	$ 7,462	$ 5,472	$ 42,364	$ 45,867

XML

Recent Accounting Pronouncements (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Basis of Presentation

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Rule 10-01 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of September 30, 2019, and its results of operations for the three and nine months ended September 30, 2019 and 2018 and cash flows for the nine months ended September 30, 2019 and 2018. The Condensed Consolidated Balance Sheet at December 31, 2018 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year.  These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (the "2018 Form 10-K"). All intercompany transactions have been eliminated.

Certain prior period amounts have been reclassified for consistency with the current period presentation.

It is our practice to establish actual quarterly closing dates using a predetermined fiscal calendar, which requires our businesses to close their books on a Saturday in order to minimize the potentially disruptive effects of quarterly closing on our business processes. Historically, the effects of this practice were generally not significant to reported results for any quarter and only existed within a reporting year. In the event that differences in actual closing dates are material to year-over-year comparisons of quarterly or year-to-date results, we will provide the appropriate disclosures. Our actual closing dates for the three and nine months ended September 30, 2019 and 2018 were September 28, 2019 and September 29, 2018, respectively.

New Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize most leases on their balance sheets related to the rights and obligations created by those leases. The new standard also requires disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will be effective for interim and annual periods beginning after December 15, 2018 (early adoption is permitted). Initial guidance stated that the new standard be applied under a modified retrospective approach with periods prior to the adoption date being adjusted. During July 2018, however, the FASB issued ASU 2018-11, Leases (Topic 842), providing another transition method allowing a company to recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption without adjusting prior periods. The Company adopted the standard effective January 1, 2019 electing the cumulative-effect adjustment approach made available in ASU 2018-11. The Company has also elected the following practical expedients:

•the package of three expedients which allows the Company not to re-assess (i) whether any expired or existing contracts are or contain leases, (ii) lease classification for any expired or existing leases, and (iii) initial direct costs for any expired or existing leases;

•the short-term lease practical expedient, which allows the Company to exclude leases with an initial term of 12 months or less (“short-term leases”) from recognition in the unaudited Condensed Consolidated Balance Sheet;

•the bifurcation of lease and non-lease components practical expedients, which did not require the Company to bifurcate lease and non-lease components for our real estate leases; and

•the land easements practical expedient, which allows the Company to carry forward the accounting treatment for land easements on existing agreements.

We have implemented internal controls and key system functionality to enable the preparation of financial information on adoption. The standard had a material impact to our Condensed Consolidated Balance Sheet but did not have a significant impact in the recognition, measurement or presentation of lease expenses within the Condensed Consolidated Statements of Operations or the Condensed Consolidated Statements of Cash Flows. The most significant impact was the recognition of right-of-use (“ROU”) assets and liabilities for operating leases, while our accounting for finance leases remained substantially unchanged. See "Note 8. Leases" for further information.

XML

Inventories (Tables)

9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Schedule of Inventory, Current

	September 30, 2019		December 31, 2018
Raw materials	$	46,714	$	55,002
Work in progress	65,146		46,728
Finished goods	57,558		39,368
Spares and other	24,618		24,555
	194,036		165,653
Reduction to LIFO cost basis	(31,557)		(28,471)
Total inventories – net	$	162,479	$	137,182

XML

Leases - Maturities of Lease Liabilities After Adoption (Details) $ in Thousands	Sep. 30, 2019 USD ($)
Operating Leases
2019 (remainder)	$ 10,987
2020	41,576
2021	29,838
2022	20,578
2023	12,391
Thereafter	70,375
Total lease payments	185,745
Less imputed interest	(49,337)
Total	136,408
Finance Leases
2019 (remainder)	194
2020	708
2021	472
2022	151
2023	0
Thereafter	0
Total lease payments	1,525
Less imputed interest	(81)
Total	$ 1,444

XML

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Finance Lease Cost
Amortization of right-of-use asset	$ 172	$ 477
Interest on lease liabilities	18	52
Total finance lease cost	190	529
Operating lease cost	9,874	25,375
Short-term lease cost	2,527	10,924
Total lease cost	$ 12,591	$ 36,828

XML

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsPlace-holder. If none exist, this note will be removed.

XML

Accounts and Other Receivables - Net (Tables)

9 Months Ended

Sep. 30, 2019

Receivables [Abstract]

Schedule of Accounts and Other Receivables Net

	September 30, 2019		December 31, 2018
Accounts receivables	$	108,832	$	166,017
Other	2,320		1,716
Total accounts and other receivables	111,152		167,733
Less – allowance for doubtful accounts	(1,860)		(7,467)
Total accounts and other receivables – net	$	109,292	$	160,266

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net income	$ 43,441	$ 45,483
Adjustments to reconcile net income to net cash (used for) provided by operating activities:
Depreciation and amortization	42,094	38,905
Loss on disposal of assets	4,967	1,560
Deferred income taxes	9,149	8,816
Stock based compensation	7,575	7,506
Accretion of deferred financing fees	320	1,696
Restructuring charges	12,623	0
Changes in assets and liabilities:
Accounts and other receivables	51,136	46,878
Inventories	(26,739)	14,182
Accounts payable	(12,844)	(10,675)
Accrued liabilities	(4,470)	(9,703)
Deferred income and customer advances	(20,608)	(14,899)
Other assets and liabilities	(6,108)	(2,014)
Net cash provided by operating activities	100,536	127,735
Cash flows from investing activities:
Expenditures for property, plant and equipment	(106,386)	(72,650)
Other investing activities	(2,203)	(1,656)
Net cash used for investing activities	(108,589)	(74,306)
Cash flows from financing activities:
Payments of long-term debt	0	(266,625)
Borrowings from line of credit	316,750	284,500
Payments of line of credit	(250,750)	(84,500)
Payment of line of credit facility fees	0	(1,362)
Principal payments of finance leases	(4,656)	(225)
Purchase of treasury stock	(53,067)	(20,443)
Issuance of common stock	16	0
Net cash provided by (used for) financing activities	8,293	(88,655)
Net change in cash and cash equivalents	240	(35,226)
Cash and cash equivalents at beginning of period	9,808	55,432
Cash and cash equivalents at the end of period	10,048	20,206
Supplemental non-cash investing activities:
Capital expenditures included in accounts payable	27,344	17,649
Supplemental cash activities:
Cash paid for interest	3,519	4,406
Cash paid for income taxes	$ 6,949	$ 7,254

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Sales	$ 310,633	$ 368,653	$ 970,743	$ 1,128,350
Costs, expenses and other:
Costs of goods sold	280,123	343,434	850,131	1,007,712
Selling, general and administrative expenses	19,261	18,057	58,683	55,189
Other non-operating expense (income), net	1,815	1,453	4,871	6,581
Total costs, expenses and other	301,199	362,944	913,685	1,069,482
Income before taxes	9,434	5,709	57,058	58,868
Income tax expense	1,513	229	13,617	13,385
Net income	$ 7,921	$ 5,480	$ 43,441	$ 45,483
Earnings per common share
Basic (in dollars per share)	$ 0.29	$ 0.18	$ 1.54	$ 1.50
Diluted (in dollars per share)	$ 0.28	$ 0.18	$ 1.49	$ 1.46
Weighted average common shares outstanding
Basic (in shares)	27,608,985	30,160,991	28,192,760	30,375,873
Diluted (in shares)	28,581,451	30,983,834	29,164,024	31,189,640

XML

Income Taxes

9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes 

The Company’s provision for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The provision for income taxes was $1.5 million and $0.2 million for the three months ended September 30, 2019 and 2018, respectively. The provision for income taxes was $13.6 million and $13.4 million for the nine months ended September 30, 2019 and 2018, respectively.

In the current period, the Company recorded an income tax benefit of $0.9 million in connection with the filing of the 2018 U.S. federal income tax return primarily attributable to additional research tax credits claimed in 2018. This resulted in a 9.9% and 1.6% decrease to the Company’s effective tax rate for the three and nine months ended September 30, 2019, respectively. In the period ended September 30, 2018, the Company recorded a net $1.0 million income tax benefit in connection with the filing of the 2017 U.S. federal income tax return and the accounting under ASC 740 (Staff Accounting Bulletin No. 118) for the Tax Cuts and Jobs Act ("Tax Act") . These adjustments resulted in a 18.2% and 1.8% decrease to the Company’s effective tax rate for the three and nine months ended September 30, 2018, respectively.

XML

Recent Accounting Pronouncements

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Recent Accounting Pronouncements

Recent Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations.

In October 2018, the FASB issued ASU No. 2018-16, Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (“SOFR”) Overnight Index Swap (“OIS”) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes, which permits use of the OIS rate based on SOFR as a U.S. benchmark interest rate for hedge accounting purposes under Topic 815 in addition to the interest rates on direct Treasury obligations of the U.S. government (“UST”), the LIBOR swap rate, the OIS rate based on the Fed Funds Effective Rate and the SIFMA Municipal Swap Rate. Pursuant to the amendments, SOFR will be an option to replace LIBOR as it is phased out. The amendments of ASU No. 2018-16 are effective for companies that have adopted ASU 2017-12 for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year or at such time a company adopts ASU 2017-12. Early adoption of ASU 2018-16 is not permitted without previous adoption of ASU 2017-12. As the Company elected to early adopt ASU 2017-12 during the fourth quarter of 2018, the Company adopted ASU 2018-16 effective January 1, 2019, which did not have a material impact on the Company's consolidated financial position or results of operations upon adoption.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize most leases on their balance sheets related to the rights and obligations created by those leases. The new standard also requires disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will be effective for interim and annual periods beginning after December 15, 2018 (early adoption is permitted). Initial guidance stated that the new standard be applied under a modified retrospective approach with periods prior to the adoption date being adjusted. During July 2018, however, the FASB issued ASU 2018-11, Leases (Topic 842), providing another transition method allowing a company to recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption without adjusting prior periods. The Company adopted the standard effective January 1, 2019 electing the cumulative-effect adjustment approach made available in ASU 2018-11. The Company has also elected the following practical expedients:

•the package of three expedients which allows the Company not to re-assess (i) whether any expired or existing contracts are or contain leases, (ii) lease classification for any expired or existing leases, and (iii) initial direct costs for any expired or existing leases;

•the short-term lease practical expedient, which allows the Company to exclude leases with an initial term of 12 months or less (“short-term leases”) from recognition in the unaudited Condensed Consolidated Balance Sheet;

•the bifurcation of lease and non-lease components practical expedients, which did not require the Company to bifurcate lease and non-lease components for our real estate leases; and

•the land easements practical expedient, which allows the Company to carry forward the accounting treatment for land easements on existing agreements.

We have implemented internal controls and key system functionality to enable the preparation of financial information on adoption. The standard had a material impact to our Condensed Consolidated Balance Sheet but did not have a significant impact in the recognition, measurement or presentation of lease expenses within the Condensed Consolidated Statements of Operations or the Condensed Consolidated Statements of Cash Flows. The most significant impact was the recognition of right-of-use (“ROU”) assets and liabilities for operating leases, while our accounting for finance leases remained substantially unchanged. See "Note 8. Leases" for further information.

XML

Inventories

9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Inventories

Inventories

	September 30, 2019		December 31, 2018
Raw materials	$	46,714	$	55,002
Work in progress	65,146		46,728
Finished goods	57,558		39,368
Spares and other	24,618		24,555
	194,036		165,653
Reduction to LIFO cost basis	(31,557)		(28,471)
Total inventories – net	$	162,479	$	137,182

The increase in Total inventories – net at September 30, 2019 compared to the balance at December 31, 2018 was due primarily to increased Work in progress and Finished goods inventory due to sales timing, product mix and buffer inventory build ahead of the Company's planned fourth quarter 2019 turnaround partially offset by lower levels of Raw materials driven by the timing of cumene deliveries.

XML

Earnings Per Share - Antidilutive Common Stock Equivalents (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2017
Earnings Per Share [Abstract]
Options and stock equivalents (in shares)	658,327	135,535	509,401	130,535

XML

Revenues - Narrative (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019 country customer	Sep. 30, 2018
Concentration Risk [Line Items]
Number of customers | customer			400
Number of countries in which customers are located (more than) | country			40
Length of contract terms			We typically sell to customers under master service agreements, with one- to two-year terms on average, or by purchase orders.
Duration of customer relationship			20 years
10 Largest Customers | Customer Concentration Risk | Revenue from Contract with Customer
Concentration Risk [Line Items]
Concentration risk percentage	51.00%	48.00%	47.00%	45.00%
Shaw Industries Group Inc | Customer Concentration Risk | Revenue from Contract with Customer
Concentration Risk [Line Items]
Concentration risk percentage	23.00%	22.00%	21.00%	22.00%

XML

Derivative and Hedging Instruments - Narrative (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Nov. 06, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Derivative loss reclassification from AOCI to income	$ 900,000
Customer Concentration Risk | Accounts Receivable | One Customer
Derivative Instruments, Gain (Loss) [Line Items]
Concentration risk percentage		22.00%
Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, notional amount	100,000,000
Derivative liability, fair value			$ 0
Derivative, amount of hedged item	$ 100,000,000

XML

Restructuring - Components of Restructuring Activities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Restructuring Reserve [Roll Forward]
Accrual balance at December 31, 2018	$ 0
Charges	4,050
Cash payments	(1,467)
Accrual balance at September 30, 2019	2,583
Employee separations
Restructuring Reserve [Roll Forward]
Accrual balance at December 31, 2018	0
Charges	1,364
Cash payments	(1,364)
Accrual balance at September 30, 2019	0
Facility exit costs
Restructuring Reserve [Roll Forward]
Accrual balance at December 31, 2018	0
Charges	2,686
Cash payments	(103)
Accrual balance at September 30, 2019	$ 2,583

XML

Commitments and Contingencies (Details)	9 Months Ended
	Sep. 30, 2019 customer
Commitments and Contingencies Disclosure [Abstract]
Number of manufacturing locations	3

XML

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Leases
Operating lease right-of-use assets	$ 136,122	$ 117,921	$ 0
Operating lease liabilities – short-term	35,656	24,794	0
Operating lease liabilities – long-term	100,752	93,127	$ 0
Total operating lease liabilities	136,408
Finance Leases
Property, plant and equipment – gross	2,633
Accumulated depreciation	(1,206)
Property, plant and equipment – net	1,427	$ 1,032
Accounts payable	676
Other liabilities	768
Total finance lease liabilities	$ 1,444
Weighted Average Remaining Lease Term
Operating leases	9 years 2 months 12 days
Finance leases	2 years 3 months 18 days
Weighted Average Discount Rate
Operating leases	5.75%
Finance leases	4.87%

XML

Postretirement Benefit Cost - Narrative (Details) - USD ($)	3 Months Ended				9 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2019
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Pension contributions		$ 3,700,000	$ 500,000	$ 0	$ 4,200,000
Scenario, Forecast
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Pension contributions	$ 0

XML

Derivative and Hedging Instruments

9 Months Ended

Sep. 30, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative and Hedging Instruments

Derivative and Hedging Instruments

The specific credit and market, commodity price and interest rate risks to which the Company is exposed in connection with its ongoing business operations are described below. This discussion includes an explanation of the hedging instrument, interest rate swap agreements, used to manage the Company’s interest rate risk associated with a fixed and floating-rate borrowing.

For cash flow hedges, the entire change in the fair value of the hedging instrument included in the assessment of hedge effectiveness is recorded in Other comprehensive income. Those amounts are reclassified to earnings in the same income statement line item that is used to present the earnings effect of the hedged item when the hedged item affects earnings.

Credit and Market Risk – Financial instruments, including derivatives, expose the Company to counterparty credit risk for non-performance and to market risk related to changes in commodity prices, interest rates and foreign currency exchange rates. The Company manages its exposure to counterparty credit risk through specific minimum credit standards, diversification of counterparties, and procedures to monitor concentrations of credit risk. The Company’s counterparties in derivative transactions are substantial investment and commercial banks with significant experience using such derivative instruments. The Company monitors the impact of market risk on the fair value and cash flows of its derivative and other financial instruments considering reasonably possible changes in commodity prices, interest rates and foreign currency exchange rates and restricts the use of derivative financial instruments to hedging activities.

The Company continually monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. The terms and conditions of credit sales are designed to mitigate or eliminate concentrations of credit risk with any

single customer. Although the Company did not have any customers accounting for a significant percentage of trade Accounts receivable - net at September 30, 2019, one customer accounted for approximately 22% of trade Accounts receivable – net at December 31, 2018.

Commodity Price Risk Management – The Company's exposure to market risk for commodity prices can result in changes in the cost of production. We primarily mitigate our exposure to commodity price risk by using long-term, formula-based price contracts with our suppliers and formula-based price agreements with customers. Our customer agreements provide for price adjustments based on relevant market indices and raw material prices and generally do not include take-or-pay terms. We may also enter into forward commodity contracts with third-parties designated as hedges of anticipated purchases of several commodities. Forward commodity contracts are marked-to-market, with the resulting gains and losses recognized in earnings, in the same category as the items being hedged, when the hedged transaction is recognized. At September 30, 2019 and 2018, we had no financial contracts related to forward commodity agreements.

Interest Rate Risk Management – The Company has entered into two interest rate swap agreements for a total notional amount of $100 million to exchange floating for fixed rate interest payments for our LIBOR-based borrowings. These interest rate swaps had a fair value of zero at inception and were effective November 30, 2018 and July 31, 2019 with respective maturity dates of November 30, 2021 and February 21, 2023. In accordance with FASB Accounting Standards Codification (“ASC”) ASC 815, the Company designated the interest rate swaps as cash flow hedges of floating-rate borrowings. The interest rate swaps convert the Company’s interest rate payments on the first $100 million of variable-rate, 1-month LIBOR-based debt to a fixed interest rate. These interest rate swaps involve the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the interest rate swap without an exchange of the underlying principal amount.

	Liability Derivatives
	September 30, 2019			December 31, 2018
	Balance Sheet Classification	Fair Value		Balance Sheet Classification	Fair Value
Derivatives designated as hedging instruments under ASC 815:
Interest Rate Contracts	Accrued liabilities and Other liabilities	(2,246)		Accrued liabilities and Other liabilities	(833)
Total Derivatives		$	(2,246)		$	(833)

The following table summarizes adjustments related to cash flow hedge included in Cash-flow hedges, in the Condensed Consolidated Statements of Comprehensive Income:

	September 30, 2019
Loss on derivative instruments included in Accumulated other comprehensive income at December 31, 2018	$	(833)
Fair value adjustment	(1,413)
Loss on derivative instruments included in Accumulated other comprehensive income at September 30, 2019	$	(2,246)

At September 30, 2019, the Company expects to reclassify approximately $0.9 million of net losses on derivative instruments from Accumulated other comprehensive income to earnings during the next 12 months due to the payment of variable interest associated with the floating rate debt.

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - shares	3 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Treasury Stock
Stock repurchased during period (in shares)	537,033	578,045	793,754	485,145	70,107	8,995

XML

Revenues (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Each of the Company’s product lines represented the following approximate percentage of total sales for the three and nine months ended September 30, 2019 and 2018:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019	2018
Nylon	25%	28%	28%	28%
Caprolactam	26%	18%	22%	18%
Ammonium Sulfate Fertilizers	20%	19%	23%	20%
Chemical Intermediates	29%	35%	27%	34%
	100%	100%	100%	100%

The Company's revenues by geographic area for the three and nine months ended September 30, 2019 and 2018 were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	250,056	$	306,050	$	797,249	$	946,195
International	60,577		62,603		173,494		182,155
Total	$	310,633	$	368,653	$	970,743	$	1,128,350

Summary of Deferred Income and Customer Advances

Below is a roll-forward of Deferred income and customer advances for the nine months ended September 30, 2019:

Opening balance January 1, 2019	$	22,556
Additions to deferred revenues	1,083
Less amounts recognized in revenues	(21,691)
Ending balance September 30, 2019	$	1,948

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 10,048	$ 9,808
Accounts and other receivables – net	109,292	160,266
Inventories – net	162,479	137,182
Other current assets	8,433	3,807
Total current assets	290,252	311,063
Property, plant and equipment – net	731,643	672,210
Operating lease right-of-use assets	136,122	0
Goodwill	15,005	15,005
Other assets	38,795	36,348
Total assets	1,211,817	1,034,626
Current liabilities:
Accounts payable	219,225	231,720
Accrued liabilities	29,839	30,448
Operating lease liabilities – short-term	35,656	0
Deferred income and customer advances	1,948	22,556
Total current liabilities	286,668	284,724
Deferred income taxes	112,579	103,783
Operating lease liabilities – long-term	100,752	0
Line of credit – long-term	266,000	200,000
Postretirement benefit obligations	22,581	21,080
Other liabilities	6,011	4,701
Total liabilities	794,591	614,288
COMMITMENTS AND CONTINGENCIES (Note 9)
STOCKHOLDERS' EQUITY
Common stock, par value $0.01; 200,000,000 shares authorized; 30,600,708 shares issued and 27,481,162 outstanding at September 30, 2019; 30,555,715 shares issued and 29,345,001 outstanding at December 31, 2018	306	306
Preferred stock, par value $0.01; 50,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2019 and December 31, 2018	0	0
Treasury stock at par (3,119,546 shares at September 30, 2019; 1,210,714 shares at December 31, 2018)	(31)	(12)
Additional paid-in capital	189,242	234,699
Retained earnings	231,260	187,819
Accumulated other comprehensive loss	(3,551)	(2,474)
Total stockholders' equity	417,226	420,338
Total liabilities and stockholders' equity	$ 1,211,817	$ 1,034,626

XML

Postretirement Benefit Cost (Tables)

9 Months Ended

Sep. 30, 2019

Retirement Benefits [Abstract]

Schedule of Net Benefit Costs

The components of Net periodic benefit cost of the Company’s pension plan are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Service cost	$	1,714	$	2,001	$	5,141	$	6,004
Interest cost	521		469		1,563		1,407
Expected return on plan assets	(334)		(287)		(1,002)		(862)
Net periodic benefit cost	$	1,901	$	2,183	$	5,702	$	6,549

XML

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 46,714	$ 55,002
Work in progress	65,146	46,728
Finished goods	57,558	39,368
Spares and other	24,618	24,555
Inventory gross	194,036	165,653
Reduction to LIFO cost basis	(31,557)	(28,471)
Total inventories – net	$ 162,479	$ 137,182

XML

Revenues - Summary of Deferred Revenue and Customer Advances (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Change in Contract with Customer, Liability [Roll Forward]
Opening balance	$ 22,556
Additions to deferred revenues	1,083
Less amounts recognized in revenues	(21,691)
Ending balance	$ 1,948

XML

Restructuring (Tables)

9 Months Ended

Sep. 30, 2019

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs

Restructuring costs for the nine months ended September 30, 2019 were as follows:

	Nine Months Ended September 30, 2019
Write-off of equipment and facility	$	7,131
Facility exit costs	2,686
Employee separations	1,364
Inventory write-downs	1,442
Total restructuring charges	$	12,623

Schedule of Restructuring Reserve by Type of Cost

The following table summarizes the components of restructuring activities and the remaining balances of accrued restructuring charges as of September 30, 2019:

	Employee Separation Benefits		Facility Exit Costs		Total
Accrual balance at December 31, 2018	$	—	$	—	$	—
Charges	1,364		2,686		4,050
Cash payments	(1,364)		(103)		(1,467)
Accrual balance at September 30, 2019	$	—	$	2,583	$	2,583

The balance of accrued restructuring charges is expected to be settled within the next twelve months.

XML

Earnings Per Share

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Earnings Per Share

Earnings Per Share

The computation of basic and diluted earnings per share ("EPS") is based on Net income divided by the basic weighted average number of common shares and diluted weighted average number of common shares, respectively. The details of the basic and diluted EPS calculations for the three and nine months ended September 30, 2019 and 2018 were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Basic
Net Income	$	7,921	$	5,480	$	43,441	$	45,483
Weighted average common shares outstanding	27,608,985		30,160,991		28,192,760		30,375,873
EPS – Basic	$	0.29	$	0.18	$	1.54	$	1.50
Diluted
Dilutive effect of equity awards and other stock-based holdings	972,466		822,843		971,264		813,767
Weighted average common shares outstanding	28,581,451		30,983,834		29,164,024		31,189,640
EPS – Diluted	$	0.28	$	0.18	$	1.49	$	1.46

Diluted EPS is computed based upon the weighted average number of common shares outstanding for the period plus the dilutive effect of common stock equivalents (which includes units allocated to the AdvanSix stock unit fund under the AdvanSix Inc. Deferred Compensation Plan) using the treasury stock method and the average market price of our common stock for the year.

The diluted EPS calculations exclude the effect of stock options when the options’ assumed proceeds exceed the average market price of the common shares during the period. The anti-dilutive common stock equivalents outstanding at the three and nine months ended September 30, 2019 and 2018 were as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019	2018
Options and stock equivalents	658,327	135,535	509,401	130,535

XML

Leases

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Leases

Leases

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use assets, Operating lease liabilities – short-term, and Operating lease liabilities – long-term in our Condensed Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment – net, Accounts payable, and Other liabilities in our Condensed Consolidated Balance Sheets.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease pre-payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease and, when it is reasonably certain that such an option will be exercised, it is included in the determination of the corresponding assets and

liabilities. Short-term leases are not recognized on our unaudited Condensed Consolidated Balance Sheets. Lease expense for all lease payments is recognized on a straight-line basis over the lease term.

We have lease agreements with lease and non-lease components, which are generally accounted for separately. Additionally, for certain equipment leases, we apply a portfolio approach to effectively account for the operating lease ROU assets and liabilities. The Company has entered into agreements to lease transportation equipment, storage facilities, office space, dock access and other equipment. The leases have initial terms of up to 20 years with some containing renewal options subject to customary conditions.

The components of lease expense were as follows:

	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Finance lease cost:
Amortization of right-of-use asset	$	172	$	477
Interest on lease liabilities	18		52
Total finance lease cost	190		529
Operating lease cost	9,874		25,375
Short-term lease cost	2,527		10,924
Total lease cost	$	12,591	$	36,828

Supplemental cash flow information related to leases was as follows:

	Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	25,089
Operating cash flows from finance leases	48
Financing cash flows from finance leases	4,656
Non-cash information:
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	38,324
Finance leases	872

Supplemental balance sheet information related to leases was as follows:

	September 30, 2019
Operating Leases
Operating lease right-of-use assets	$	136,122
Operating lease liabilities – short term	35,656
Operating lease liabilities – long term	100,752
Total operating lease liabilities	$	136,408
Finance Leases
Property, plant and equipment – gross	$	2,633
Accumulated depreciation	(1,206)
Property, plant and equipment – net	$	1,427
Accounts payable	676
Other liabilities	768
Total finance lease liabilities	$	1,444
Weighted Average Remaining Lease Term
Operating leases	9.2 years
Finance leases	2.3 years
Weighted Average Discount Rate
Operating leases	5.75		%
Finance leases	4.87		%

The cumulative effect of the changes made to the Condensed Consolidated Balance Sheets for the adoption of the new leasing standard on January 1, 2019 was as follows:

	Balance Sheet accounts prior to new leasing standard adoption adjustments		Adjustments due to the adoption of the new leasing standard		Balance Sheet accounts after the new leasing standard adoption adjustments
ASSETS
Property, plant and equipment – net	$	1,032	$	—	$	1,032
Operating lease right-of-use assets	—		117,921		117,921
Total assets	1,034,626		$	117,921	1,152,547
LIABILITIES AND EQUITY
Current Liabilities:
Accounts payable	$	318	$	—	$	318
Operating lease liabilities – short term	—		24,794		24,794
Total current liabilities	284,724		24,794		309,518
Operating lease liabilities – long term	—		93,127		93,127
Other liabilities	762		—		762
Total liabilities	614,288		117,921		732,209
Total equity	420,338		—		420,338
Total liabilities and equity	1,034,626		$	117,921	1,152,547

Maturities of lease liabilities were as follows:

Year Ending December 31,	Operating Leases		Finance Leases
2019 (remainder)	$	10,987	$	194
2020	41,576		708
2021	29,838		472
2022	20,578		151
2023	12,391		—
Thereafter	70,375		—
Total lease payments	185,745		1,525
Less imputed interest	(49,337)		(81)
Total	$	136,408	$	1,444

As previously disclosed in our 2018 Form 10-K and under the previous lease accounting standard, future minimum lease payments for leases having initial or remaining non-cancellable lease terms in excess of one year were as follows:

Year Ending December 31,	Operating Leases		Capital Leases
2019	$	36,110	$	239
2020	29,318		212
2021	16,111		131
2022	11,571		89
2023	9,104		—
Thereafter	26,627		—
Total lease payments	$	128,841	$	671

Leases

Leases

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use assets, Operating lease liabilities – short-term, and Operating lease liabilities – long-term in our Condensed Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment – net, Accounts payable, and Other liabilities in our Condensed Consolidated Balance Sheets.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease pre-payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease and, when it is reasonably certain that such an option will be exercised, it is included in the determination of the corresponding assets and

liabilities. Short-term leases are not recognized on our unaudited Condensed Consolidated Balance Sheets. Lease expense for all lease payments is recognized on a straight-line basis over the lease term.

We have lease agreements with lease and non-lease components, which are generally accounted for separately. Additionally, for certain equipment leases, we apply a portfolio approach to effectively account for the operating lease ROU assets and liabilities. The Company has entered into agreements to lease transportation equipment, storage facilities, office space, dock access and other equipment. The leases have initial terms of up to 20 years with some containing renewal options subject to customary conditions.

The components of lease expense were as follows:

	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Finance lease cost:
Amortization of right-of-use asset	$	172	$	477
Interest on lease liabilities	18		52
Total finance lease cost	190		529
Operating lease cost	9,874		25,375
Short-term lease cost	2,527		10,924
Total lease cost	$	12,591	$	36,828

Supplemental cash flow information related to leases was as follows:

	Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	25,089
Operating cash flows from finance leases	48
Financing cash flows from finance leases	4,656
Non-cash information:
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	38,324
Finance leases	872

Supplemental balance sheet information related to leases was as follows:

	September 30, 2019
Operating Leases
Operating lease right-of-use assets	$	136,122
Operating lease liabilities – short term	35,656
Operating lease liabilities – long term	100,752
Total operating lease liabilities	$	136,408
Finance Leases
Property, plant and equipment – gross	$	2,633
Accumulated depreciation	(1,206)
Property, plant and equipment – net	$	1,427
Accounts payable	676
Other liabilities	768
Total finance lease liabilities	$	1,444
Weighted Average Remaining Lease Term
Operating leases	9.2 years
Finance leases	2.3 years
Weighted Average Discount Rate
Operating leases	5.75		%
Finance leases	4.87		%

The cumulative effect of the changes made to the Condensed Consolidated Balance Sheets for the adoption of the new leasing standard on January 1, 2019 was as follows:

	Balance Sheet accounts prior to new leasing standard adoption adjustments		Adjustments due to the adoption of the new leasing standard		Balance Sheet accounts after the new leasing standard adoption adjustments
ASSETS
Property, plant and equipment – net	$	1,032	$	—	$	1,032
Operating lease right-of-use assets	—		117,921		117,921
Total assets	1,034,626		$	117,921	1,152,547
LIABILITIES AND EQUITY
Current Liabilities:
Accounts payable	$	318	$	—	$	318
Operating lease liabilities – short term	—		24,794		24,794
Total current liabilities	284,724		24,794		309,518
Operating lease liabilities – long term	—		93,127		93,127
Other liabilities	762		—		762
Total liabilities	614,288		117,921		732,209
Total equity	420,338		—		420,338
Total liabilities and equity	1,034,626		$	117,921	1,152,547

Maturities of lease liabilities were as follows:

Year Ending December 31,	Operating Leases		Finance Leases
2019 (remainder)	$	10,987	$	194
2020	41,576		708
2021	29,838		472
2022	20,578		151
2023	12,391		—
Thereafter	70,375		—
Total lease payments	185,745		1,525
Less imputed interest	(49,337)		(81)
Total	$	136,408	$	1,444

As previously disclosed in our 2018 Form 10-K and under the previous lease accounting standard, future minimum lease payments for leases having initial or remaining non-cancellable lease terms in excess of one year were as follows:

Year Ending December 31,	Operating Leases		Capital Leases
2019	$	36,110	$	239
2020	29,318		212
2021	16,111		131
2022	11,571		89
2023	9,104		—
Thereafter	26,627		—
Total lease payments	$	128,841	$	671

XML

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income taxes	$ 1,513	$ 229	$ 13,617	$ 13,385
Out of period adjustment resulting in an income tax expense (benefit)		$ (1,000)	$ (900)
Increase (decrease) in effective income tax rate due to period period adjustments	9.90%	18.20%	1.60%	1.80%

XML

Derivative and Hedging Instruments - Adjustments Related to Cash Flow Hedges on the Comprehensive Income Statement (Details) - Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
AOCI Attributable To Parent, Before Tax [Roll Forward]
Loss on derivative instruments included in Accumulated other comprehensive income at December 31, 2018	$ (833)
Fair value adjustment	(1,413)
Loss on derivative instruments included in Accumulated other comprehensive income at September 30, 2019	$ (2,246)

XML

Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation of Revenue [Line Items]
Percentage of sales	100.00%	100.00%	100.00%	100.00%
Sales	$ 310,633	$ 368,653	$ 970,743	$ 1,128,350
United States
Disaggregation of Revenue [Line Items]
Sales	250,056	306,050	797,249	946,195
International
Disaggregation of Revenue [Line Items]
Sales	$ 60,577	$ 62,603	$ 173,494	$ 182,155
Nylon
Disaggregation of Revenue [Line Items]
Percentage of sales	25.00%	28.00%	28.00%	28.00%
Caprolactam
Disaggregation of Revenue [Line Items]
Percentage of sales	26.00%	18.00%	22.00%	18.00%
Ammonium Sulfate Fertilizers
Disaggregation of Revenue [Line Items]
Percentage of sales	20.00%	19.00%	23.00%	20.00%
Chemical Intermediates
Disaggregation of Revenue [Line Items]
Percentage of sales	29.00%	35.00%	27.00%	34.00%

XML

Derivative and Hedging Instruments (Tables)

9 Months Ended

Sep. 30, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

	Liability Derivatives
	September 30, 2019			December 31, 2018
	Balance Sheet Classification	Fair Value		Balance Sheet Classification	Fair Value
Derivatives designated as hedging instruments under ASC 815:
Interest Rate Contracts	Accrued liabilities and Other liabilities	(2,246)		Accrued liabilities and Other liabilities	(833)
Total Derivatives		$	(2,246)		$	(833)

Derivative Instruments, Gain (Loss)

The following table summarizes adjustments related to cash flow hedge included in Cash-flow hedges, in the Condensed Consolidated Statements of Comprehensive Income:

	September 30, 2019
Loss on derivative instruments included in Accumulated other comprehensive income at December 31, 2018	$	(833)
Fair value adjustment	(1,413)
Loss on derivative instruments included in Accumulated other comprehensive income at September 30, 2019	$	(2,246)

XML

Accounts and Other Receivables - Net (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Receivables [Abstract]
Accounts receivables	$ 108,832	$ 166,017
Other	2,320	1,716
Total accounts and other receivables	111,152	167,733
Less – allowance for doubtful accounts	(1,860)	(7,467)
Total accounts and other receivables – net	109,292	$ 160,266
Accounts receivable, allowance for doubtful accounts write-off	$ 5,100

XML

Accounts and Other Receivables - Net

9 Months Ended

Sep. 30, 2019

Receivables [Abstract]

Accounts and Other Receivables - Net

Accounts and Other Receivables – Net

	September 30, 2019		December 31, 2018
Accounts receivables	$	108,832	$	166,017
Other	2,320		1,716
Total accounts and other receivables	111,152		167,733
Less – allowance for doubtful accounts	(1,860)		(7,467)
Total accounts and other receivables – net	$	109,292	$	160,266

The decrease in Total accounts and other receivables – net at September 30, 2019 versus December 31, 2018 was due primarily to lower sales and increased collections related to a trade receivables discount arrangement with a third-party financial institution. The change in the allowance for doubtful accounts relates primarily to an accounts receivable write-off of approximately $5.1 million related to a customer bankruptcy as previously reported in the 2018 Form 10-K.

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

The Company is subject to a number of lawsuits, investigations and disputes, some of which involve substantial amounts claimed, arising out of the conduct of the Company or other third-parties in the normal and ordinary course of business. A liability is recognized for any contingency that is probable of occurrence and reasonably estimable. The Company continually assesses the likelihood of adverse judgments or outcomes in these matters, as well as potential ranges of possible losses (taking into consideration any insurance recoveries), based on an analysis of each matter with the assistance of legal counsel and, if applicable, other experts.

Given the uncertainty inherent in such lawsuits, investigations and disputes, the Company does not believe it is possible to develop estimates of reasonably possible loss in excess of current accruals for these matters. Considering the Company’s past experience and existing accruals, the Company does not expect the outcome of these matters, either individually or in the aggregate, to have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. Potential liabilities are subject to change due to new developments, changes in settlement strategy or the impact of evidentiary requirements, which could cause the Company to pay damage awards or settlements (or become subject to equitable remedies) that could have a material adverse effect on the Company’s consolidated results of operations, balance sheet and/or operating cash flows in the periods recognized or paid.

We assumed from Honeywell all health, safety and environmental (“HSE”) liabilities and compliance obligations related to the past and future operations of our current business, as well as all HSE liabilities associated with our three current manufacturing locations and the other locations used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to be material for 2019.

XML

Fair Value Measurements (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty agreement, asset, fair value		$ 1.0
Fair Value, Inputs, Level 2 | Interest Rate Contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, fair value	$ (2.2)

XML

Restructuring - Restructuring Costs (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Total restructuring charges	$ 12,600	$ 12,623	$ 0
Write-off of equipment and facility
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		7,131
Employee separations
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		2,686
Facility exit costs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		1,364
Inventory write-downs
Restructuring Cost and Reserve [Line Items]
Total restructuring charges		$ 1,442

XML

Leases - Supplemental Cash Flow Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 25,089
Operating cash flows from finance leases	48
Financing cash flows from finance leases	4,656
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	38,324
Finance leases	$ 872

XML

Postretirement Benefit Cost - Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Retirement Benefits [Abstract]
Service cost	$ 1,714	$ 2,001	$ 5,141	$ 6,004
Interest cost	521	469	1,563	1,407
Expected return on plan assets	(334)	(287)	(1,002)	(862)
Net periodic benefit cost	$ 1,901	$ 2,183	$ 5,702	$ 6,549

XML

Leases - Future Minimum Lease Payments Before Adoption (Details) $ in Thousands	Dec. 31, 2018 USD ($)
Operating Leases
2019	$ 36,110
2020	29,318
2021	16,111
2022	11,571
2023	9,104
Thereafter	26,627
Total lease payments	128,841
Capital Leases
2019	239
2020	212
2021	131
2022	89
2023	0
Thereafter	0
Total lease payments	$ 671

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	30,600,708	30,555,715
Common stock, shares outstanding (in shares)	27,481,162	29,345,001
Preferred stock par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Treasury stock (in shares)	3,119,546	1,210,714

XML

Leases (Tables)

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Components of Lease Expense

The components of lease expense were as follows:

	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Finance lease cost:
Amortization of right-of-use asset	$	172	$	477
Interest on lease liabilities	18		52
Total finance lease cost	190		529
Operating lease cost	9,874		25,375
Short-term lease cost	2,527		10,924
Total lease cost	$	12,591	$	36,828

Supplemental cash flow information related to leases was as follows:

	Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	25,089
Operating cash flows from finance leases	48
Financing cash flows from finance leases	4,656
Non-cash information:
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	38,324
Finance leases	872

Supplemental Balance Sheet Information

Supplemental balance sheet information related to leases was as follows:

	September 30, 2019
Operating Leases
Operating lease right-of-use assets	$	136,122
Operating lease liabilities – short term	35,656
Operating lease liabilities – long term	100,752
Total operating lease liabilities	$	136,408
Finance Leases
Property, plant and equipment – gross	$	2,633
Accumulated depreciation	(1,206)
Property, plant and equipment – net	$	1,427
Accounts payable	676
Other liabilities	768
Total finance lease liabilities	$	1,444
Weighted Average Remaining Lease Term
Operating leases	9.2 years
Finance leases	2.3 years
Weighted Average Discount Rate
Operating leases	5.75		%
Finance leases	4.87		%

Schedule of New Accounting Pronouncements

The cumulative effect of the changes made to the Condensed Consolidated Balance Sheets for the adoption of the new leasing standard on January 1, 2019 was as follows:

	Balance Sheet accounts prior to new leasing standard adoption adjustments		Adjustments due to the adoption of the new leasing standard		Balance Sheet accounts after the new leasing standard adoption adjustments
ASSETS
Property, plant and equipment – net	$	1,032	$	—	$	1,032
Operating lease right-of-use assets	—		117,921		117,921
Total assets	1,034,626		$	117,921	1,152,547
LIABILITIES AND EQUITY
Current Liabilities:
Accounts payable	$	318	$	—	$	318
Operating lease liabilities – short term	—		24,794		24,794
Total current liabilities	284,724		24,794		309,518
Operating lease liabilities – long term	—		93,127		93,127
Other liabilities	762		—		762
Total liabilities	614,288		117,921		732,209
Total equity	420,338		—		420,338
Total liabilities and equity	1,034,626		$	117,921	1,152,547

Maturities of Finance Lease Liabilities

Maturities of lease liabilities were as follows:

Year Ending December 31,	Operating Leases		Finance Leases
2019 (remainder)	$	10,987	$	194
2020	41,576		708
2021	29,838		472
2022	20,578		151
2023	12,391		—
Thereafter	70,375		—
Total lease payments	185,745		1,525
Less imputed interest	(49,337)		(81)
Total	$	136,408	$	1,444

Maturities of Operating Lease Liabilities

Maturities of lease liabilities were as follows:

Year Ending December 31,	Operating Leases		Finance Leases
2019 (remainder)	$	10,987	$	194
2020	41,576		708
2021	29,838		472
2022	20,578		151
2023	12,391		—
Thereafter	70,375		—
Total lease payments	185,745		1,525
Less imputed interest	(49,337)		(81)
Total	$	136,408	$	1,444

Schedule of Future Minimum Rental Payments for Operating Leases

As previously disclosed in our 2018 Form 10-K and under the previous lease accounting standard, future minimum lease payments for leases having initial or remaining non-cancellable lease terms in excess of one year were as follows:

Year Ending December 31,	Operating Leases		Capital Leases
2019	$	36,110	$	239
2020	29,318		212
2021	16,111		131
2022	11,571		89
2023	9,104		—
Thereafter	26,627		—
Total lease payments	$	128,841	$	671

Schedule of Future Minimum Lease Payments for Capital Leases

As previously disclosed in our 2018 Form 10-K and under the previous lease accounting standard, future minimum lease payments for leases having initial or remaining non-cancellable lease terms in excess of one year were as follows:

Year Ending December 31,	Operating Leases		Capital Leases
2019	$	36,110	$	239
2020	29,318		212
2021	16,111		131
2022	11,571		89
2023	9,104		—
Thereafter	26,627		—
Total lease payments	$	128,841	$	671

XML

Cover Page - shares	9 Months Ended
	Sep. 30, 2019	Oct. 25, 2019
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	1-37774
Entity Registrant Name	AdvanSix Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-2525089
Entity Address, Address Line One	300 Kimball Drive
Entity Address, Address Line Two	Suite 101
Entity Address, City or Town	Parsippany
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07054
City Area Code	973
Local Phone Number	526-1800
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ASIX
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		27,912,355
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001673985
Amendment Flag	false

XML

Restructuring

9 Months Ended

Sep. 30, 2019

Restructuring and Related Activities [Abstract]

Restructuring

Restructuring On May 2, 2019, the Company approved the closure of its Pottsville, Pennsylvania films plant as part of its broader strategic efforts to improve the Company’s competitive position in providing quality film products and services to its customers. The Company also announced a strategic alliance with Oben Holding Group S.A. (“Oben”), a third-party producer of films for the flexible packaging industry, leveraging the Company's sales channels and Nylon 6 supply with Oben's new state-of-the-art manufacturing facility. The Company ceased operations at the Pottsville, Pennsylvania plant in July 2019.

Restructuring costs consist of long-lived asset impairments, facility exit costs, employee separations and inventory write-downs. Facility exit costs include demolition, equipment relocation, contract terminations and project management costs. These costs are included in Cost of goods sold in the Condensed Consolidated Statements of Operations. The Company recorded a restructuring charge of $12.6 million in the second quarter of 2019 and does not expect to incur any additional restructuring charges related to the closure of its films plant.

Restructuring costs for the nine months ended September 30, 2019 were as follows:

	Nine Months Ended September 30, 2019
Write-off of equipment and facility	$	7,131
Facility exit costs	2,686
Employee separations	1,364
Inventory write-downs	1,442
Total restructuring charges	$	12,623

The following table summarizes the components of restructuring activities and the remaining balances of accrued restructuring charges as of September 30, 2019:

	Employee Separation Benefits		Facility Exit Costs		Total
Accrual balance at December 31, 2018	$	—	$	—	$	—
Charges	1,364		2,686		4,050
Cash payments	(1,364)		(103)		(1,467)
Accrual balance at September 30, 2019	$	—	$	2,583	$	2,583

The balance of accrued restructuring charges is expected to be settled within the next twelve months.

XML

Organization, Operations and Basis of Presentation

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Organization, Operations and Basis of Presentation

Organization, Operations and Basis of Presentation

Description of Business

AdvanSix Inc. (“AdvanSix”, the “Company”, "we" or "our") is an integrated manufacturer of Nylon 6, a polymer resin which is a synthetic material used by our customers to produce engineered plastics, fibers, filaments and films that, in turn, are used in such end-products as automotive and electronic components, carpets, sports apparel, fishing nets and food and industrial packaging. As a result of our backward integration and the configuration of our manufacturing facilities, we also sell a variety of other products, all of which are produced as part of our integrated Nylon 6 resin manufacturing process including caprolactam, ammonium sulfate fertilizers, acetone and other chemical intermediates.

Basis of Presentation

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Rule 10-01 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of September 30, 2019, and its results of operations for the three and nine months ended September 30, 2019 and 2018 and cash flows for the nine months ended September 30, 2019 and 2018. The Condensed Consolidated Balance Sheet at December 31, 2018 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year.  These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (the "2018 Form 10-K"). All intercompany transactions have been eliminated.

Certain prior period amounts have been reclassified for consistency with the current period presentation.

It is our practice to establish actual quarterly closing dates using a predetermined fiscal calendar, which requires our businesses to close their books on a Saturday in order to minimize the potentially disruptive effects of quarterly closing on our business processes. Historically, the effects of this practice were generally not significant to reported results for any quarter and only existed within a reporting year. In the event that differences in actual closing dates are material to year-over-year comparisons of quarterly or year-to-date results, we will provide the appropriate disclosures. Our actual closing dates for the three and nine months ended September 30, 2019 and 2018 were September 28, 2019 and September 29, 2018, respectively.

Liabilities to creditors to whom we have issued checks that remained outstanding at September 30, 2019 and December 31, 2018 aggregated $5.4 million and $7.7 million, respectively, and were included in Cash and cash equivalents and Accounts payable in the Condensed Consolidated Balance Sheets.

The Company submitted a business interruption insurance claim related to the first quarter 2018 weather event and recorded a benefit of $6.6 million and $2.3 million to Cost of goods sold in the first and second quarters of 2019, respectively. The business interruption claim was closed during the second quarter of 2019 with a total recorded benefit of approximately of $12 million.

On May 4, 2018, the Company announced that its Board of Directors (the “Board”) authorized a share repurchase program of up to $75 million of the Company’s common stock. On February 22, 2019, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity available under the May 2018 share repurchase program. Repurchases may be made from time to time on the open market, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.

As of September 30, 2019, the Company had repurchased 3,089,762 shares of common stock for an aggregate of $90.4 million at a weighted average market price of $29.26 per share. As of September 30, 2019, $59.6 million remained available for share repurchases under the current authorization.

XML

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Schedule of Earnings Per Share

The details of the basic and diluted EPS calculations for the three and nine months ended September 30, 2019 and 2018 were as follows: 

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Basic
Net Income	$	7,921	$	5,480	$	43,441	$	45,483
Weighted average common shares outstanding	27,608,985		30,160,991		28,192,760		30,375,873
EPS – Basic	$	0.29	$	0.18	$	1.54	$	1.50
Diluted
Dilutive effect of equity awards and other stock-based holdings	972,466		822,843		971,264		813,767
Weighted average common shares outstanding	28,581,451		30,983,834		29,164,024		31,189,640
EPS – Diluted	$	0.28	$	0.18	$	1.49	$	1.46

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The anti-dilutive common stock equivalents outstanding at the three and nine months ended September 30, 2019 and 2018 were as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019	2018
Options and stock equivalents	658,327	135,535	509,401	130,535